Solventum Corporation (NYSE: SOLV) — A Real Repair Job Priced as a Finished One

An independent equity research note. Report date: 2026-07-31 Price reference: $86.82 (close, 2026-07-30) · Market cap $15,065M · Enterprise value $19,584M Sector: Health Care · Medical Devices & Health Information Technology Coverage status: Initiation Note on timing: Q2-2026 results had not been reported as of this report date. The last audited/reviewed hard data is the Q1-2026 Form 10-Q filed 2026-05-05. Management has guided the Street to a Q2 print scheduled for 2026-08-05.

This note carries no buy/sell recommendation and no price target. The single, deliberate exception is the labeled Claude's Take block immediately below. Sections 1–15 are position-free. General information only — not investment advice.

⚡ Claude’s Take

The author’s own independent opinion, deliberately set apart from the rest of this note; general information only and not investment advice. The analytical body (Sections 1–15) below carries no position and no price target.

Verdict: AVOID at $86.82 — a genuine repair job that is now fully paid for. Accumulate on weakness in the ~$62–72 zone (≈11–12x honest earnings, ≈1.4–1.6x sales), not here. Not a short: the assets are real and the balance sheet is fixed.

Tag: The cash hasn’t shown up yet, but the multiple already has.

Solventum at 13.2x the high end of its own FY2026 adjusted-EPS guide looks like ordinary cheap medtech. It isn’t, because the denominator is the least cash-supported in its peer group. FY2025 add-backs equalled 88% of adjusted pre-tax income and only 27% of them were non-cash amortisation — the rest is perpetual restructuring, a mass tort Solventum owns forever by contract, and a ~$650M/year separation run-rate whose own definition includes 3M’s profit mark-ups on services Solventum must eventually staff itself. The verifiable result: FY2025 adjusted net income of $1,070M converted to negative $10M of free cash flow, and the gap widened to −$273M in Q1-2026. A reverse-DCF at $86.82 requires levered free cash flow of roughly $700M–$1,000M. Management’s own long-range plan delivers about $920M — the current price therefore embeds the entire 2027 convergence and leaves nothing for execution risk, on a convergence with zero quarters of evidence behind it. Meanwhile the break-up everyone is waiting for is already in the price: a sum-of-the-parts on mid-range public comps lands near $79/share against a $86.82 quote, and only clears the price if Health Information Systems fetches a premium to a faster-growing, far better-disclosed Waystar.

The framing is repaired value / special situation in the first days of a momentum breakout it has not yet earned — not a falling knife, and specifically not a crowded momentum trade. The factor evidence is unusually clear: SOLV loads negative on Momentum (−0.25) and essentially zero on Value (+0.04) in the Base+Sector+Industry model, with 56% of its variance idiosyncratic — a corporate-action stock, not a style stock. The all-time closing high of $88.55 on 2026-07-29 is three sessions old, rests on a UBS upgrade rather than any company disclosure, and arrives with P/S at the 99.7th percentile of Solventum’s own (shallow, 28-month) history, a 14.7% 3M stake with a live shelf overhead, H1-2026 flattered by a pre-announced ~$100M advance-ordering pull-forward that reverses in H2, and an unprinted quarter due 2026-08-05. That is confirmation arriving at the least convenient possible moment. What I would happily own is the business underneath — ~27% returns on tangible operating capital, a 38%-margin HIS segment carrying 30% of segment profit on 17% of sales, a grouper written by name and version number into state Medicaid regulation — and I would own it at a price that pays me for an unreserved 8,400-plaintiff mass tort going to bellwether trial in 2026 and for Epic launching autonomous coding in November 2026. $86.82 does not.

Conviction: medium. Flips bullish on two consecutive quarters of genuinely positive free cash flow with separation expense falling below ~$75M/quarter — that single fact would validate the whole bridge and I would be wrong to have waited. Flips bearish on an adverse Bair Hugger bellwether verdict, or on HIS organic growth breaking to zero in the two quarters bracketing Epic’s launch; either would attack the only part of the story that is genuinely differentiated.

📈 Stock Price Action — Five-Year Event Map

Note: Solventum has only ~28 months of trading history — the spin from 3M completed 2024-04-01 — so this is a two-and-a-half-year map, not a five-year one.

From an all-time closing low of $48.02 (2024-07-09), SOLV has round-tripped to an all-time closing high of $88.55 (2026-07-29) and closed at $86.82 on 2026-07-30 — ~2.0% off that high, inside a 52-week range of $62.49–$88.55. The path was violent, not smooth: three separate drawdowns of −40.0%, −25.0% and −27.5% in 28 months. (The all-time intraday high of $96.05, set in the first when-issued session on 2024-03-26, has never been reclaimed.)

Cycle narrative. (1) The spin was priced as a growth-free, $8.3B-levered orphan and traded like one: −40% from the first when-issued close to the July 2024 low, with the debt raised on Solventum’s balance sheet but the cash remitted to 3M. (2) The recovery was bought on evidence of self-help — two acceptable prints, then the Thermo Fisher transaction, which converted a low-growth segment into ~$4.10B of deleveraging cash and produced the largest up-session of the first year. (3) The February–April 2025 give-back was macro, not company-specific: the tariff drawdown hit a low-beta healthcare name alongside everything else, and the +8.8% snap-back on the pause confirms it. (4) Through mid-2025 the market paid for balance-sheet repair actually executed — the P&F close, the note tenders, and, decisively, the first $1.0B buyback authorization; 3M’s 8.8m-share secondary at $73.45 was absorbed on a single −2.4% session. (5) The winter 2026 drawdown was a credibility event: FY25 free cash flow printed at −$10M against $150–250M guided, and the stock lost 27.5% in 88 days. (6) The recovery since 2026-04-07 has been a self-help-plus-activist re-rating — notably, Trian’s public campaign moved the stock only 1.3% on announcement day; the gains came later, through the Q1-26 print and conference commentary. (7) The final leg to the all-time closing high is three sessions old and its proximate catalyst was a sell-side rating change ahead of the Q2-2026 print scheduled for 2026-08-05.

1. Executive Summary

Solventum is 3M’s former Health Care Business Group, spun off on 2024-04-01 with roughly $8.3 billion of newly raised debt, essentially all of which was remitted to 3M. It is not one business. It is three genuinely unrelated franchises — acute-care wound and infection-prevention consumables (MedSurg, ~62% of continuing revenue), dental and orthodontic materials (Dental Solutions, ~18%), and hospital revenue-cycle software (Health Information Systems, ~17%) — sharing no call point, no channel, no manufacturing and no R&D platform. The fourth segment, Purification & Filtration, was sold to Thermo Fisher on 2025-09-01 for ~$4.0 billion cash, producing a $1,549M pre-tax gain that corrupts every trailing GAAP metric on every screen.

The business underneath is better than the consolidated numbers suggest, and the reported earnings are worse. On tangible operating capital, Solventum earns roughly 27%; HIS earns a 36–38% operating margin with essentially zero capitalised software and carries 30% of segment profit on 17% of sales. But the consolidated economics have gone backwards since separation: revenue rose $128M from FY2023 to FY2025 while adjusted operating income fell $292M; adjusted EPS went $6.70 (FY2024) → $6.11 (FY2025) → a guided $6.40–6.60 (FY2026), still below the FY2024 level two years on; and MedSurg’s segment margin has fallen 1,080bp from 23.9% (FY2023) to 13.1% (Q1-2026).

The single most important fact in this report is the cash gap. FY2025 adjusted net income of $1,070M converted into negative $10M of free cash flow, against $150–250M guided. Q1-2026 free cash flow was −$273M, versus −$80M a year earlier. FY2026 is guided to ~$200M — a 1.3% free-cash-flow yield. Management asserts that ex-separation the “clean” figure would be ~$1.0B. That assertion is the entire investment case, and there is not yet one quarter of evidence for it.

Valuation, therefore, is a debate about the denominator, not the multiple. At $86.82 the stock trades at 13.2x the high end of guided adjusted EPS — mid-cohort, essentially on top of BDX — but at 18.5x GAAP EBITDA excluding the divestiture gain, the joint-highest in its peer group, on 2–3% organic growth. A reverse-DCF requires $700M–$1,000M of levered free cash flow across the plausible WACC/growth box; management’s long-range plan delivers about $920M and no more. A sum-of-the-parts on mid-range public comps lands near $79/share — below the current price — and clears it only if HIS commands a premium to Waystar. The break-up an activist is demanding appears already to be in the price.

Capital allocation has been better than the incentives deserve. The P&F sale was genuinely value-creating (sold at roughly four times the multiple Solventum’s own equity commands); 79% of proceeds retired 5.4–6.0% debt including the worst tranches; net leverage fell from ~3.8x to 2.4x; the one acquisition (Acera Surgical, $776M) is small and on-strategy; there is correctly no dividend. Against that, the compensation plan contains no return-on-capital metric anywhere, and the Talent Committee paid a 123%-of-target bonus in a year of negative GAAP free cash flow by adding $540M back to the FCF metric — a metric whose target had already been lowered for the same costs. Say-on-pay support fell from 85.9% to 74.2%; Trian went public on 2026-04-30.

The risks are not symmetric. Solventum is the economic defendant — it indemnifies 3M, manages the litigation and pays the costs — in the Bair Hugger MDL: more than 8,400 US lawsuits with bellwether trials anticipated in 2026, against $31M of total accrued litigation and an explicit statement that no range of loss above the accrual can be estimated. 3M’s PFAS indemnity for Solventum products expired 2025-12-31 with no reserve disclosed. And HIS — the profit engine — faces Epic (43.7% of US hospitals, 56.9% of beds) launching fully autonomous ED and radiology coding in November 2026, while Solventum won zero 2026 Best-in-KLAS awards across six adjacent categories and discloses no RPO, backlog, retention or contract duration.

The honest summary: a real repair job, executed competently, on assets 3M under-defended for a decade — now priced as though the repair is finished, the cash has arrived, and the tail risk does not exist.

2. Business Overview

2.1 What Solventum actually is

Solventum sells in more than 90 countries and employed 20,584 people at end-2025, down from 22,007 in 2023 [FACT — FY2025 10-K Item 1]. It reports three segments after the P&F disposal, plus an “All Other” line containing the retained drinking-water filtration business and legacy 3M supply arrangements.

The P&F divestiture, precisely. The Transaction Agreement with Thermo Fisher Scientific was signed 2025-02-25; an Amended & Restated Agreement on 2025-06-25 carved the drinking-water business out of scope; the sale closed 2025-09-01. Cash consideration was approximately $4.0 billion (announced at ~$4.10B), with $3,890M landing in FY2025 investing cash flow, producing a pre-tax gain of $1,549M net of $86M of transaction fees. Roughly 200 transition service agreements run to a target completion in 2027, and Solventum booked a $113M unfavourable contract liability for services it agreed to provide below fair market value, of which $56M was recognised as an SG&A benefit in 2025. Thermo is entitled to up to $75M from Solventum on a future Water sale or after three years ($64M accrued). [FACT — FY2025 10-K Note 3 and MD&A; 8-Ks 2025-02-27, 2025-06-25, 2025-09-02]

The one acquisition. Acera Surgical (synthetic tissue matrices for wound care) closed 2025-12-23 for $776M — $696M cash net of cash acquired plus $80M fair-valued milestone ($125M face, by 2030) — allocating $440M to intangibles on an ~8-year life and $441M to non-deductible goodwill, all into MedSurg. It contributed $28M of reported sales in Q1-2026 [FACT — FY2025 10-K Note 3; Q1-2026 10-Q].

2.2 Segment revenue and growth

2021–2023 per the Form 10 information statement on the then-four-segment basis; P&F restated in the FY2025 10-K after the Water carve-out. 2024–Q1-26 per the FY2025 10-K and Q1-2026 10-Q.

The arithmetic that frames everything: reported revenue went from $8,171M (2021) to $8,325M (2025) — a four-year CAGR of +0.5%. Under 3M this base compounded organically at roughly 1.2–1.6% a year against markets Solventum itself sized at 3–8% growth. The 2025 step to +3.3% is the first genuine break in the pattern, and management’s claim to have “tripled comparable annual sales growth” is directionally supported — but the base being tripled was close to nothing. [FACT — Form 10 MD&A; FY2025 10-K MD&A]

2.3 The profitability divergence

Since 2021, MedSurg’s margin has fallen ~970bp and Dental’s ~890bp, while HIS’s has risen ~600bp. Some product-side compression is transitional — stranded standalone costs, 3M supply-agreement mark-ups, ~$55M of 2025 tariffs guided to $100–120M in 2026, elevated logistics through the ERP and distribution-centre cutovers. But the direction is not ambiguous: the two businesses that sell physical things are losing operating leverage and the one that sells software is gaining it. In FY2025 HIS delivered 18.1% of reportable-segment sales but 30.0% of reportable-segment operating income; in Q1-2026, 21.7% of sales and 34.4% of operating income.

2.4 Revenue mix, geography, customers

The residual software figure matches HIS segment revenue almost exactly in every year tested (2023: $1,285M vs $1,285M; 2024: $1,306M vs $1,306M; Q1-26: $342M vs $342M). HIS is effectively 100% software and services; the entire “rental” line is negative-pressure-wound-therapy units placed under operating leases. [FACT — FY2025 10-K consolidated income statement; Note 2]

Practically all product revenue is consumable and reorder-driven; genuine capital equipment is a rounding error. The two razor-and-blade structures are NPWT (rented therapy units pulling proprietary dressings) and sterilization assurance (placed Attest auto-readers pulling single-use indicators). The only true subscription revenue is HIS: unearned revenue of $621M at 12/31/25 (46% of HIS revenue), which the 10-K says “primarily relates to revenue that is recognized over time for one-year software license contracts” — a disclosure that matters greatly to the competitive-position analysis below.

Geography: United States $4,668M (56.1%) and International $3,657M (43.9%) in FY2025. FY2025 organic growth was +3.7% US vs +2.7% international; in Q1-2026 the gap widened sharply to +4.4% US vs −1.1% international. No customer exceeded 10% of revenue or receivables in any of 2023, 2024 or 2025 [FACT — FY2025 10-K Note 18].

Customers: acute-care hospitals and IDNs, ASCs, skilled-nursing and the patient home (MedSurg); dental practices, DSOs and distributors (Dental); hospitals, health systems, payers and government agencies (HIS). Channel is mixed, but management was explicit on the Q1-2026 call that in the US “the majority of our sales go through distribution.” That matters: for a large slice of MedSurg the economic buyer is a GPO-mediated purchasing committee, not the clinician.

2.5 Named franchises

MedSurg — Advanced Wound Care: NPWT under V.A.C., ActiV.A.C., Veraflo, Prevena and AbThera on the Granufoam platform, plus iOn PROGRESS remote monitoring and V.A.C. Peel & Place; dressings under Tegaderm, Promogran/Prisma and Coban; skin care under Cavilon; Acera’s synthetic tissue matrices. Infection Prevention & Surgical Solutions: Tegaderm CHG — which the Form 10 describes as “the only transparent CHG dressing cleared by the FDA”; temperature management under Bair Hugger and Ranger; sterilization assurance under Attest; Ioban antimicrobial incise drapes; Micropore/Coban/Durapore tapes; Red Dot electrodes; Littmann stethoscopes; and a Medical Technologies OEM line supplying designed-in adhesives and microfluidic films into CGMs and point-of-care diagnostics.

Dental Solutions: Filtek direct restoratives (Solventum estimates >2 billion restorations over twenty years) with Scotchbond adhesives and Elipar curing; RelyX cements, Impregum and Protemp; Clinpro prevention; and orthodontics under Clarity brackets and Clarity Aligners.

Health Information Systems: revenue-cycle management around 360 Encompass plus autonomous coding; clinician productivity under M*Modal (Fluency Direct, CDI Engage One); and performance management built on the 3M Grouper methodologies — APR-DRG and related classification systems developed with CMS and used for payment, benchmarking and reporting in multiple countries. [FACT — Form 10 information statement, “Our Segments”]

2.6 Verdict — Business Overview

A ~$8.0B collection of three genuinely unrelated healthcare franchises of sharply unequal quality, whose consolidated numbers flatter the weak parts and obscure the good one. MedSurg is 62% of continuing sales but a declining-margin, GPO-exposed consumables business whose growth has repeatedly lagged its own estimate of market growth. Dental is a habit-driven materials franchise recovering from a real end-market recession, with a shrinking orthodontics tail. HIS is the crown jewel — 17% of sales, 30% of segment profit, 36–38% margins, essentially zero capital employed, and accelerating. The portfolio has no shared call point, no shared channel, no shared manufacturing and no shared R&D platform; the only thing the three businesses have in common is corporate overhead. That is not a business; it is a holding company — which is precisely why an activist is asking for it to be taken apart.

3. Industry Dynamics

3.1 The framing problem: Solventum is not in an industry, it is in five

Any single verdict on “SOLV’s industry” is wrong by construction. The compact statement of the whole section is the Q1-2026 segment print, which shows three businesses diverging violently within a single quarter:

The largest business earns the worst margin and is losing 470bp a year. The smallest earns 38.1% and is gaining 500bp.

3.2 Per-market structure map

*Share claims are Solventum’s own and date from the March-2024 Form 10; the post-spin 10-Ks contain no market-share claim and no third-party share citation for any segment.

3.3 The Greenwald ROIC cross-section — the decisive table

¹ Excludes the $1,549M P&F gain. ² ROIC.ai reports EBITDA in the operating-margin field for UK filers — not comparable to the US operating margins in the same column. ³ Core EBIT, constant FX. Source: ROIC.ai accessed 2026-07-31, reconciled to filings.

Greenwald’s profitability test holds that sustained after-tax ROIC of 15–25% indicates competitive advantage and 6–8% indicates its absence. Not one company in Solventum’s named competitive set clears 11%. The best two — Align at 10.0% and Steris at 9.2% — sit at or below a plausible cost of capital. Three destroy capital outright. The honest caveat is that much of this reflects goodwill from serial acquisition, and returns on operating assets are far higher (see the returns-on-capital discussion below). But the persistence of impairments across the entire group is itself the finding: these are industries where roll-up acquirers systematically overpaid because organic growth was unavailable. Solventum inherits that condition — goodwill $5,704M plus intangibles $2,592M is 58% of total assets against $1,326M of net PP&E.

3.4 Advanced wound care — structurally fine, but a reimbursement bomb just went off

The category is not commoditising uniformly. Smith+Nephew’s FY2025 split is the cleanest evidence: Advanced Wound Care (dressings) $766M +2.6%; Bioactives $621M +6.8%; Devices (NPWT/PICO) $406M +9.8%. The dressing half is a share-and-price fight; the device and bioactive halves compound. Solventum’s Advanced Wound Care grew +2.0% (FY2025) and +2.1% (Q1-2026) — the dressing rate, despite owning the category-defining NPWT franchise. Corroborating this, NPWT rental revenue has been flat: $616M / $600M / $615M (2023/24/25).

Peers are improving: ConvaTec’s ROIC rose 6.8%→9.5% over three years on a stable 56% gross margin; Mölnlycke runs a 28% EBITDA margin; Coloplast a 28% EBIT margin. Smith+Nephew’s wound segment earns a 24.9% trading margin against Solventum’s entire MedSurg at 13.1%. Since peers are holding or improving while Solventum’s product gross margin fell 560bp, the margin problem is company-specific, not industry-wide.

The live shock is CMS. Medicare Part B spending on skin substitutes in non-facility settings went from $252M (2019) to over $10bn (2024). The CY2026 Physician Fee Schedule final rule reclassified skin substitutes from biologicals to “incident-to” supplies at a single blended $127.28/cm² rate effective 2026-01-01. The consequences are immediate: MiMedx wound revenue −60%; ConvaTec’s InnovaMatrix −30% with a $72M impairment and a quantified 2% FY26 group headwind. Solventum bought Acera Surgical — synthetic tissue matrices — in December 2025, directly into this blast radius, and has quantified nothing. [OPEN QUESTION — the highest-priority unquantified exposure in MedSurg]

3.5 Infection prevention & surgical — the demand engine has stalled

This is Solventum’s largest product line (~35% of revenue), and the company itself describes it as operating in “highly competitive and fragmented end markets,” naming nine competitors. Greenwald’s rule of thumb applies: if you cannot count the top firms on one hand, there are probably no barriers.

The critical external fact is that surgical volumes are declining. HCA Healthcare, same-facility:

Admissions rise while surgeries fall, and the decline is accelerating. Solventum’s IPSS line is levered to surgical case counts, not admissions — which directly explains IPSS decelerating from +4.5% organic (FY2025) to +0.6% (Q1-2026). Hospitals themselves are squeezed: median operating margin 2.1% in January 2026 (from 4.9% in December), with 40% of executives planning to cut or defer capital spending. A customer at a 2.1% margin does not accept vendor price increases.

Sterilization assurance is the exception and the best niche Solventum owns. ANSI/AAMI ST79 requires a biological indicator in every sterilization load containing implants, with revalidation triggered by any process change and audited by the Joint Commission. Mesa Labs’ pure-play sterilization segment earned a 71.3% gross margin in FY2026. But the barrier is procedural, not impregnable — Mesa grew that segment +8.7% for the year and +17.7% in Q4, and Steris’s Healthcare consumables grew +7%, against Solventum’s IPSS at +0.6%. Solventum sits in the best structural niche it owns and is apparently not winning in it.

3.6 Dental — the worst industry Solventum is in

The structural problem is the market, and ADA Health Policy Institute data state it definitively. Real US consumer spending on dental rose from $185bn (Jan-2020) to $201bn (Sep-2025) = +9%. Over the identical window physician services rose 24% and overall health care 22%. Dental has under-grown the rest of US healthcare consumption by ~13 percentage points in five years. It is the part of healthcare consumers defer.

Capacity is loosening — dentists reporting “not busy enough” rose to 33% (Q4-25) from 24% (Q4-24); new-patient wait times fell to 13.4 days from a 22.7-day peak. The pricing record is an indictment: indexed to Jan-2015 = 100, by Sep-2025 dental staff wages 144, CPI 138, dental supplies PPI 129 — consumables makers have lost ~9 points of real price over a decade. Envista’s 2025 “3 points of price” was two-thirds tariff pass-through, guided back to “a point or so” for 2026.

Yet the dispersion settles the “bad industry” question: Straumann +8.9% organic at a 26.5% core EBIT margin versus Dentsply −3.0%, a $598M net loss, $650M of impairments, a cancelled dividend and four CEOs in eight years. A 13-point spread in the same year and the same markets means execution, not structure, drives outcomes. Solventum Dental is mid-pack on growth and top-decile on margin (25.6%).

Two live risks: DSO consolidation (16.1% of dentists affiliated, but 27% of those <10 years out; ~130 PE-backed platforms) — though no evidence of DSO-driven private-label substitution could be found, and portfolio breadth arguably advantages Solventum. And China VBP 2.0: framework due July 2026, supplier selection August 2026, with brackets in scope. Implants took a ~63% price cut in 2023; Straumann’s Q4-25 APAC organic fell −12.8% on anticipation alone. No evidence VBP has reached restoratives, cements or bonding — Solventum’s core.

3.7 Health Information Systems — the best economics and the most acute threat

HIS is three businesses, and conflating them is the standard analytical error:

1. A regulatory annuity — the APR-DRG grouper. Proprietary, Solventum-maintained, commercially licensed, versus CMS’s free MS-DRG. Embedded by name and version number in state Medicaid regulation: Mississippi (v43), South Carolina (v32→v42), Wisconsin (v42), Florida (v43), and Missouri as a new adopter in July 2025. Displacing it requires amending state regulations, re-deriving weights, re-running budget neutrality and renegotiating every hospital contract. Free MS-DRG has existed for decades and has not displaced it, because MS-DRG handles paediatrics and obstetrics — the Medicaid population — poorly. Generative AI does not touch this: an AI coder still codes to the grouper. This is a Greenwald government-protected barrier, the most durable category, and it is still expanding. It is also almost certainly the smallest piece of HIS, and undisclosed. [OPEN QUESTION]
2. A contested core — CAC/CDI/autonomous coding.
3. A melting adjacency — M*Modal speech recognition, in “expected double-digit declines,” described in both the FY2024 and FY2025 10-Ks as hit by “changing market conditions.” 3M paid roughly $1bn for M*Modal in 2019; it won Best in KLAS; it is now in double-digit decline because ambient LLM documentation did not exist when it was bought. That is the best-documented precedent inside Solventum’s own portfolio for what could happen to coding — and Marathon is explicit that the capital cycle does not protect incumbents where technology disrupts the business model.

The central risk is Epic. Epic holds 43.7% of US acute hospitals and 56.9% of beds (KLAS, 2026-05-14), a fifth consecutive year of gains. Epic’s revenue-cycle agent Penny already serves 240+ organisations for professional-fee coding, already ships NoteReader CDI natively, and launches fully autonomous coding for ED and radiology in November 2026. Solventum’s autonomous coding is listed in Epic Toolbox: part of its distribution runs through its competitor.

Two facts temper any “unassailable moat” framing. In the 2026 Best in KLAS awards Solventum won nothing across six adjacent categories — CAC went to Dolbey for the tenth consecutive year, CDI to Microsoft Nuance, the inaugural Autonomous Coding award to CodaMetrix, ambient to Abridge. And Solventum’s own product page lists inpatient and ED autonomous coding as “Coming soon” on a base of 195 facilities, while CodaMetrix already has 220+ hospitals. Management’s claim to be “the largest and most capable autonomous coding vendor” is unverified and in tension with its own disclosure.

The demand tailwind is not rising code counts (ICD-10-CM new codes went 252→487→190 for FY25/26/27, and the FY2027 IPPS proposed rule collapses severity-tiered MS-DRGs). The real tailwind is adjudication friction — net revenue leakage of $48.4bn in 2025, +25% — and the HCC v28 specificity squeeze: HCC categories rose 86→115 while mappable ICD-10-CM codes fell 9,797→7,770 (−21%). Documentation intensity rose because the code set shrank.

3.8 Cross-cutting factors

Pricing power: absent in aggregate. Management states price contributes “plus or minus 1%” and expects the same in 2026. A diversified healthcare portfolio that cannot take price against 2–3% inflation and a $100M+ tariff shock has no pricing power. The Q1-2026 10-Q reveals the dispersion: Dental and HIS took price; MedSurg could not, and lost 470bp.

Tariffs: $55M (2025) → $100–120M guided (2026), ~1.2–1.4% of revenue. The legal basis reset on 2026-02-20 when the Supreme Court struck down the IEEPA tariffs 6–3; a Section 122 10% global tariff replaced them within hours — but Section 122 is capped at 150 days, with Section 232 medical-device investigations open. Solventum reaffirmed guidance after the ruling, implying either expected re-imposition or unbooked recovery. [OPEN QUESTION]

PFAS: de-risked on regulation, not on supply. The FDA determined on 2025-08-06 that fluoropolymers in medical devices are safe with no reason to restrict; ECHA’s March-2026 EU restriction carries significantly increased derogations including fluoropolymers. The residual risk is supply and liability: 3M ceased supplying PFAS-containing components at end-2025 and the forward indemnity has lapsed (see Changes and Headwinds).

EU MDR: a barrier being deliberately lowered — a mild negative for incumbents. MDR certification runs €8,000 (Class I) to over €600,000 (Class III); BD discloses ~$100M+/yr. That fixed cost favoured large-portfolio incumbents. The Commission’s 2025-12-16 simplification proposal — removing fixed 5-year recertification, estimated >€3.3bn of annual savings — makes it cheaper for smaller and Asian entrants to hold EU access in exactly the commodity categories where Solventum is weakest.

The barrier Solventum rents rather than owns. The FY2025 10-K discloses that 3M is the sole source for chemical materials behind ~$3bn of revenue (36%) — naming transparent IV film dressings, biological indicators for sterilization assurance, medical securement tapes, and dental composites and cements — including one material with a 3M-proprietary process behind ~$2bn (24%). Solventum may need to “develop our own manufacturing capabilities… or identify an appropriate substitution or product reformulation.” The material-science barrier protecting Attest, Tegaderm and Filtek belongs to 3M. Solventum holds a time-limited contractual right to buy across it — and 3M supply-agreement mark-ups are a disclosed driver of MedSurg’s margin decline. This is the most under-appreciated structural fact in the name.

3.9 Marathon capital-cycle placement

The healthcare-AI pool shows every Marathon boom precondition, but it is already clearing: Rock Health M&A went 118 (2024) → 195+ (2025) → 115 in H1-2026 alone; Abridge’s valuation has been flat at $5.3bn since June 2025; and Rock Health retired its “AI deal” classification in Q1-2026 because AI is “no longer a distinguishing product or strategy” — the definition of commoditisation. This cuts both ways: the boom compresses returns for everyone including the incumbent, but in three years Solventum faces fewer, better-capitalised competitors, not more.

At Solventum’s own level, capex/depreciation rose ~1.5× → 1.8× → 2.1× (2023–25). Normally a red flag — but this is forced separation capex to replicate 3M’s plants, distribution and ERP, not industry capacity. It damages Solventum’s returns without improving anyone’s competitive position.

3.10 Verdict — Industry Dynamics

A below-average industry mix, in the worst possible configuration: the best industry is the smallest and most disrupted, while the weakest is the largest.

MedSurg (~62%) — below average. Solventum’s own filings call its largest product line’s markets “highly competitive and fragmented,” naming nine competitors. The demand driver is contracting: HCA’s surgical volumes fell in two consecutive quarters and the decline is accelerating, while hospital customers operate at 2.1% margins. Advanced wound care is genuinely average-to-decent and peers are improving — which is precisely why Solventum’s 560bp of product gross-margin loss must be read as company-specific. Sterilization assurance is a genuinely good business Solventum is under-exploiting.

Dental (~18%) — poor. A market that has under-grown the rest of US healthcare by 13 points in five years, where manufacturers have lost ~9 points of real price in a decade, and where China VBP is a live July/August 2026 catalyst on brackets. Only the wide execution dispersion keeps this from being a write-off.

HIS (~17%) — the best economics in the portfolio and the most acute threat to them. A 38.1% operating margin, a genuinely durable government-protected grouper franchise, and a payer-friction tailwind — set against Epic at 56.9% of beds launching autonomous coding in November 2026, zero Best-in-KLAS wins, inpatient autonomous coding still “coming soon,” a double-digit-declining speech franchise, and one-year licence contracts.

The one structural point that redeems the picture: across the peer set, ConvaTec, Mölnlycke, Coloplast and Smith+Nephew’s wound segment all expanded margins over the same window in which Solventum’s collapsed. That asymmetry is the section’s most important finding — Solventum’s problem is substantially the cost of being a newly independent company that still buys its critical inputs from its former parent, not the industries it competes in. Those industries are mediocre. They are not the reason MedSurg earns 13.1%.

4. Competitive Position

4.1 A disclosure problem that must be stated first

The post-spin 10-Ks — FY2024 and FY2025 — contain no market-share claim, no “market leader” claim, and no third-party share citation for any segment. Every share statement in the record dates from the March-2024 Form 10 and rests on 2022–2023-vintage third-party reports. Management now asserts leadership only verbally on calls. Greenwald’s primary test — market-share stability — cannot be run on disclosed data, and any analyst who claims to have run it is inventing numbers.

What can be done is the indirect inference, and it is unflattering. Against Solventum’s own Form 10 addressable-market growth estimates — MedSurg ~$26B growing 3–5%, Dental ~$17B growing 4–6%, HIS ~$9B growing 6–8% — the company grew +1.2%, −0.4% and +1.6% organically in 2024. On its own numbers, Solventum lost share in all three segments that year. FY2025 (+3.5% / +3.3% / +4.0%) closes most of the gap in MedSurg and Dental but still leaves HIS at the low end of its own market range. By Greenwald’s calibration — more than 5 points of share change over 5–8 years means no barriers, under 2 points means formidable ones — four years of sub-market growth points to moderate barriers eroding slowly: a real-but-under-defended position rather than either a fortress or a commodity. The mitigating evidence is that the 2025–26 recovery came entirely from volume, not price (“almost all volume,” per management), which is what a share recovery looks like, not a price-harvesting endgame.

4.2 MedSurg — a barbell of three real moats and a large commodity tail

I.V. site management (Tegaderm CHG) — genuine demand-side captivity, the best-defended line in the segment. The mechanism is protocol embedding, not brand. CHG dressings sit inside hospital CLABSI-prevention bundles written into infection-control policy and tracked against CMS hospital-acquired-condition penalties; changing supplier is a clinical-governance decision requiring re-approval, re-education and outcome monitoring. The Form 10’s claim that it is the only FDA-cleared transparent CHG dressing adds a regulatory single-source element. The financial metric that would deteriorate without it: the ability to convert customers from cheap standard transparent films to a premium antimicrobial dressing at a large price step-up. The proof is in the disclosure — Tegaderm CHG was the single largest named organic-growth driver of MedSurg in both FY2025 and Q1-2026, and management says it remains “significantly underpenetrated.”

Sterilization assurance (Attest) — razor/blade plus regulatory-validation switching cost. Placed auto-readers consume a single-use indicator every sterilization cycle, and the result is a legally retained record. Re-validating against a different indicator/reader combination is costly, slow and audit-visible. But pressure-test it against the record: sterilization assurance was an explicit drag on MedSurg in FY2024, recovering in FY2025 only on the back of new Attest launches. A razor/blade business with a genuine validation moat should not go backwards. The most plausible reading is that the installed base was under-supported — backorders, no new product, a generalist sales force — rather than that the moat is absent. This line is the single cleanest ongoing test of whether the inherited moats are intact.

NPWT — a real razor/blade plus a channel asset, but a decayed patent position. Three legs: the rented therapy-unit installed base pulling device-specific dressings ($615M of annual operating-lease revenue is the razor); a home-care DME operation that delivers equipment, monitors therapy remotely and collects from payers — infrastructure a dressing manufacturer cannot cheaply replicate; and a clinical-evidence base including a company-sponsored RCT on Prevena (4× lower surgical-site-complication incidence, 3× lower readmission). What it is not is a technology monopoly. The original KCI patents are long expired; Smith+Nephew (PICO), Mölnlycke (Avance) and Convatec (Avelle) all field single-use NPWT, and the FY2025 10-K added Medaxis to the named competitor list — a new entrant, itself evidence of low entry barriers at the periphery.

Bair Hugger — a franchise, not a moat. Solventum faces more than 8,400 US lawsuits plus a Canadian putative class action alleging surgical-site infections, and under the Separation and Distribution Agreement it indemnifies 3M for uninsured liabilities, manages the litigation and pays the legal expenses. The installed-base claim (“9 of the 10 top US hospitals”) is credible. But a franchise carrying an unquantified mass-tort tail into trial is a liability wearing a brand, and it cannot be counted as a durable advantage.

Littmann — the one true consumer-style brand, bought by individual clinicians, effectively the category default, transferred intergenerationally through nursing and medical schools. Real demand advantage via habit — and immaterial: ~26% of a ~$663M global market, i.e. the entire world stethoscope market is about one-third the size of Solventum’s wound-care line. Do not mistake a beloved brand for an economically significant one.

Tapes, wraps, electrodes, drapes — no moat, and the company says so. The Form 10’s own language: these are “highly competitive and fragmented end markets,” and — the sentence that should end the debate — “we believe we create a compelling value proposition for our distributor and Group Purchasing Organization (GPO) partners, which helps to offset a fiercely competitive pricing environment.” That is a company describing itself as a price-taker across a large share of a segment that is 62% of revenue. The SKU rationalization program — a 60bp organic drag in 2025 rising to ~100bp in 2026, the majority landing in IPSS — is management pruning exactly this tail, which is the right decision and simultaneously an admission of what the tail is worth.

MedSurg verdict: a narrow, line-item moat, not a segment-wide one. The financial proof is exactly what that mix predicts: a segment margin that has fallen from 26.5% to 13.1% while the differentiated lines grew and the commodity lines were exited.

4.3 Dental Solutions — habit-based captivity in restoratives, no position in orthodontics

The mechanism is specification habit. Dentists standardize on a restorative chemistry — Filtek’s shade system, the Scotchbond protocol, RelyX handling — and reorder by default; switching means relearning handling characteristics and accepting aesthetic-outcome risk on live patients. A genuine demand advantage, though a modest one: the friction is measured in weeks of practice, not in validated processes or regulatory filings. The financial metric: a 25.6% segment margin and the ability to take ~1% of price. That margin was 34.5% in 2021 — the captivity is real but it has not prevented an 890bp compression.

Orthodontics is a different story and management barely defends it. The FY2025 MD&A concedes “a decline in traditional orthodontic products”; the Q1-2026 MD&A concedes “a decrease in orthodontics solutions.” Clarity Aligners is a sub-scale entrant in a category where Align Technology’s own filings and industry data put ALGN at ~60–62% share, facing AngelAlign growing volume +48% at roughly half its ASP, with Align’s revenue per case falling three consecutive years. A sub-scale entrant in a category whose leader is losing pricing power is not a growth option; it is a candidate for the SKU-rationalization list.

Dental verdict: a real but narrow habit-based advantage in core restoratives, in a post-bust end market whose supply side now favours incumbents; no advantage at all in orthodontics. The FY2025/Q1-2026 acceleration is substantially backorder recovery (“more of a one-time thing,” per management) and new-product launches off a weak base.

4.4 Health Information Systems — the single most important moat question in the name

The claimed moat. Management’s case: (1) “close to a million plus” proprietary reimbursement-coding rules built “over decades”; (2) proprietary datasets accumulated at hospital scale; (3) “pretty long contracts, multiple-year contracts”; (4) a compliance/trust barrier — coding errors cost revenue and create False Claims Act exposure; (5) “we actually see AI as an opportunity more than we do a threat… we’re differentially capable of using AI”; (6) scale — “the largest and most trusted coding partner.” Management projects that “close to 50% of our customers” move to autonomous coding during the current plan period.

The evidence for. This is not what disruption looks like. HIS organic growth accelerated from +1.6% (FY2024) to +4.0% (FY2025) to +4.7% (Q1-2026), and segment margin expanded from 33.0% to 36.5% to 38.1% on “sales price growth, product mix and lower external license fees.” A franchise being displaced does not simultaneously grow faster and price better. Structurally, the strongest asset is not the software at all — it is the grouper and classification methodologies, closer to a standard-setting position than a product. Around it, 360 Encompass owns the coder workflow and M*Modal Fluency Direct interoperates with more than 250 EHRs.

The evidence against, stated plainly.

First, one flank is already lost. Clinician productivity — the M*Modal line competing head-on with Nuance/Microsoft DAX, Abridge and Ambience — has declined every year since 2024 and is guided to double-digit declines in 2026. Management has stopped defending it and now frames HIS growth exclusively around RCM, autonomous coding and international. That is the AI-native part of the market, and Solventum is losing it outright. Treat this as the leading indicator, not a footnote.

Second, the contract claim is unverified and sits awkwardly against the company’s own accounting. Solventum discloses no remaining performance obligation, no backlog, no renewal rate, no net revenue retention and no contract-duration statistic anywhere in the FY2025 10-K or the Q1-2026 10-Q. The only hard contractual datum is the revenue-recognition note: unearned revenue “primarily relates to revenue that is recognized over time for one-year software license contracts.” Multi-year commitments can coexist with annual license recognition — but management’s “multiple-year contracts” is an assertion, and the one piece of primary evidence points the other way. This is the largest disclosure gap in the name and the reason the HIS moat cannot be sized.

Third, the competitive set is formidable and shifting. The FY2025 10-K names Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar, Athena, “and a host of start-up technologies actively working to disrupt” revenue-cycle management and clinician productivity. Note what changed from the Form 10’s list: R1 RCM, Ensemble, Google and AWS were dropped, Waystar added — and Solventum now has a commercial partnership with Ensemble on autonomous coding. Partnering with a firm you previously called a competitor, inside your highest-margin franchise, reads two ways: distribution reach, or an admission that the outsourcer is becoming the customer-facing layer and you are becoming a component supplier to it.

Fourth — the argument deserving most weight — autonomous coding is self-cannibalizing to the moat. The switching cost in HIS is the coder’s workflow: the queries, the CDI collaboration, the revenue-integrity exposure during a cutover. Management’s own value proposition for autonomous coding is “eliminating FTE cost infrastructure” — that is, removing the coders. Once the coders are gone, the workflow lock is gone with them, and the purchase decision collapses to accuracy, price and audit defensibility, all of which are demonstrable and therefore contestable. The rules-and-classification layer survives that collapse; the workflow layer does not.

Fifth, “data” and “AI” are not moats. Coding rules derive from public CMS regulation, ICD/CPT code sets and payer policy — laborious to encode, not secret. The proprietary element is the labelled outcome data, and that is exactly what a competitor partnered with a large RCM outsourcer or a large health system can accumulate. Any claim of a data network effect here is speculative. There is no network effect anywhere in Solventum’s portfolio: no product becomes more valuable to a customer because other customers use it, and management does not claim one.

HIS verdict: a real but narrowing moat, resting on regulatory/standard-setting embedding in the grouper methodologies plus coder-workflow captivity in 360 Encompass, with the clinician-productivity flank already breached. The accelerating growth and expanding margins are good enough to reject the crude “legacy franchise being disrupted” thesis. They are nowhere near good enough to underwrite HIS as a durable wide-moat software asset — because Solventum discloses none of the metrics that would settle it.

4.5 The 3M inheritance problem

R&D intensity has not risen post-spin — it has fallen. R&D as a percentage of sales: 9.4% (2021), 9.4% (2022), 9.2% (2023), 9.4% (2024), 8.9% (2025) — and R&D dollars fell in 2025 to $739M from $775M. Management attributes the decline to a 3M reimbursement of technical development costs tied to supply-chain separation, which is plausible, but the four-year picture is flat-to-down. R&D headcount is ~2,000, down from >2,100 in 2023.

The vitality-index claim is the strongest evidence of the harvest — and it is unverifiable. In the CEO’s 2026-05-05 shareholder letter: “Our vitality index has more than doubled from where we started.” On the Q1-2026 call the figure given was “from 2% to the mid-teens.” These are inconsistent framings of the same claim (a doubling versus a sevenfold increase), and the metric is not defined or disclosed in any SEC filing. A 2% vitality index at spin, if accurate, would mean almost nothing in the portfolio had been recently launched — a damning statement about 3M’s stewardship. Treat the number as an unverified management assertion; treat the direction — that 3M ran this base for cash — as well supported by flat 2021–2024 organic growth and the absence of a single acquisition in 2024.

The moat is real but was under-defended, not fabricated. Evidence the assets are genuine: Tegaderm CHG’s single-source clearance and its status as the largest growth driver two periods running; Attest’s validated-process razor/blade; NPWT’s rental base and RCT evidence; the grouper’s embedding in payment policy; HIS’s 36–38% margins earned on $3M of annual depreciation. Evidence they were under-defended: sub-market growth in every segment in 2024; a sterilization business that went backwards; dental backorders bad enough that fixing them produced two quarters of growth; and a generalist sales organization into which, in the CEO’s own words, “those products were being launched into a void.” On the evidence, this is a harvested asset base with real assets underneath — a materially better position than a harvested asset base with commodity assets underneath.

4.6 The portfolio problem, and the activist

There is no operating synergy between acute-care consumables, dental materials, and hospital revenue-cycle software. No shared call point, channel, manufacturing or R&D platform. A portfolio whose parts do not reinforce each other has no portfolio-level moat — it has three separate ones, and pays a fourth layer of cost to hold them together.

Trian Fund Management (Nelson Peltz), holding ~7.09 million shares (~4.1%), published an open letter and slide deck to the board on 2026-04-30 arguing Solventum remains “significantly under-managed” post-spin and demanding three actions: rightsize overhead toward 3M-era levels, divest non-core businesses — explicitly including the immediate separation of Health Information Systems — and prioritize buybacks. [FACT — Trian press release via GlobeNewswire, 2026-04-30; Reuters, 2026-05-01]

On whether an HIS strategic review is underway: there is no 8-K and no management statement announcing one. The closest is the CEO’s Q1-2026 answer: “when others view our businesses as either strategically more relevant to them or financially attractive, we will pay attention… the further the spin gets in the rearview mirror, the more flexibility we have” — a reference to spin-related tax constraints easing with time. Treat an HIS separation as a plausible, un-announced possibility, not a fact.

4.7 Verdict — Competitive Position

No durable company-wide competitive advantage — three separate franchises of unequal quality, the best of which an activist wants sold. Solventum is not a crowded-market commodity business; the good lines are genuinely good and the moat mechanisms are nameable and tied to identifiable financial outcomes. But it is not a moated compounder either. It is a collection of narrow, line-item advantages that 3M under-defended for a decade, being commercially rebuilt and simultaneously pruned, with no portfolio-level logic binding them together and no disclosure adequate to test whether the best of them is holding. The honest verdict is weak/narrow advantage at the company level, with genuine advantage in three specific lines — Tegaderm CHG, Attest, and the HIS coding/classification core — which between them are worth more than the consolidated numbers suggest and are precisely the assets a break-up would surface.

5. Growth History and Forward Opportunities

5.1 The historical record is the problem the equity has to overcome

Four-year reported revenue CAGR of +0.5% (2021 $8,171M → 2025 $8,325M). Organic growth of +2.9%, +1.4%, +1.2%, +3.3% and +2.1% (Q1-2026). Against Solventum’s own market-growth estimates of 3–5% (MedSurg), 4–6% (Dental) and 6–8% (HIS), the company under-grew every one of its markets in every period since the spin. Some of that is deliberate — the SKU rationalization drag of 60bp in 2025 rising to ~100bp in 2026 — and pruning fiercely-priced commodity SKUs is the right call. But even grossed up for it, 3–4% is at best in line with a blended market rate, not ahead of it.

5.2 Organic vs. acquired, and the composition of the 2025 improvement

The FY2025 step from +1.2% to +3.3% is real but its composition matters. On management’s own account it comprises: backorder recovery in Dental (the CEO: “more of a one-time thing”); new-product launches into a sales organization that previously launched “into a void”; Tegaderm CHG conversion, which management calls “significantly underpenetrated”; and new Attest launches recovering a line that had been declining. Three of the four are catch-up, not compounding. Only the Tegaderm CHG penetration story is a multi-year runway on current evidence.

Acquired growth is negligible: Acera contributed $28M in Q1-2026 (~1.4% of quarterly revenue) and roughly $90M annualising. The 2024 acquisition count was zero.

5.3 The forward opportunity set, ranked by credibility

1. Tegaderm CHG penetration (high credibility). Named largest MedSurg growth driver two periods running; sole FDA-cleared transparent CHG dressing; protocol-embedded; management explicitly says underpenetrated. This is the most defensible growth line in the company.
2. HIS autonomous coding (high value, contested). Management targets “close to 50% of our customers” migrating during the plan period, and argues 80–90% of coding is ultimately automatable. The economics are excellent where it lands — but the competitive-position analysis below establishes that it is self-cannibalizing to the switching cost, and Epic ships competing capability in November 2026.
3. Commercial-model rebuild (medium). Over a thousand specialized reps globally, a Chief Commercial Officer consolidating the segments (Heather Knight, effective 2025-11-10), ~20 new products over two years. Rational response to a diagnosed under-commercialization. Early evidence is real but thin.
4. Acera / regenerative wound (medium-low, unquantified risk). A ~$900M–1bn market growing ~10% — into which the CY2026 CMS skin-substitute reset just detonated a $10bn reimbursement pool (see Industry Dynamics). Solventum has quantified nothing. [OPEN QUESTION]
5. International (low, currently negative). Q1-2026 international organic was −1.1% against US +4.4%. Dental was the only international segment growing.
6. Clarity Aligners (negative). Sub-scale against a leader losing pricing power; the MD&A concedes orthodontics is declining.

5.4 What management has promised

The long-range plan is 4–5% organic growth, 23–25% adjusted operating margin, 10% EPS CAGR and >80% FCF conversion. FY2026 is guided to 2–3% organic (3–4% ex-SKU rationalization). Note carefully: the 23–25% margin target is a return to the FY2023 carve-out margin of ~24.4%, not an advance beyond it. The plan is to get back to where 3M had it, not to a new level.

5.5 Verdict — Growth

Low-quality growth improving from a very low base — genuine, but predominantly catch-up rather than compounding, and not yet demonstrated to exceed market rates. The 2025 acceleration is real and management deserves credit for it; the composition (backorder recovery, launches into a previously starved channel, a razor/blade line recovering from decline) is what a repair looks like, not what a franchise compounding looks like. The one genuinely durable growth line is Tegaderm CHG. The one with the biggest prize — autonomous coding — is also the one most exposed to competitive displacement within eighteen months. Nothing in the growth record supports paying a premium multiple, and the forward plan’s own ceiling is the margin 3M used to earn.

6. Financial Quality

6.1 The one thing that matters: reported earnings are fiction, and the anchor is $6.25

Every screen is wrong on this name. TTM GAAP diluted EPS of $8.17 contains a $1,397M ($7.97/share) after-tax gain on the P&F sale. Strip it out:

FACT: on a clean GAAP basis Solventum earned approximately $35 million — roughly $0.20 a share — over the trailing twelve months on $8.26 billion of revenue. The correct earnings anchor is $6.25 TTM adjusted / $6.40–$6.60 FY2026 guided, not $8.17.

A second correction worth making explicitly: the continuing revenue base is not ~$6.5–7B. P&F was never presented as discontinued operations. FY2025 reportable segments ($7,526M) plus All Other ($302M) equal $7,828M; Q4-2025 ($1,998M) and Q1-2026 ($2,007M) are both fully post-P&F, giving a run-rate of ~$8.0B and an implied FY2026 of ~$8.1–8.2B.

6.2 Multi-year P&L: five straight years of margin erosion

FY2021–22 from carve-out data; FY2023–25 from the FY2025 10-K; adjusted figures from the Q4-2024, Q4-2025 and Q1-2026 8-K EX-99.1 reconciliations. FY2023 adjusted operating income is a construction (GAAP ex-$56M gain plus $365M amortization) — management published no FY2023 non-GAAP figure and the carve-out did not bear full standalone public-company cost, so treat it as directional. [ASSUMPTION]

FACT: gross margin has fallen 670bp since FY2021 and 380bp since FY2023. SG&A/sales has risen 900bp since FY2023.

The adjusted quarterly trend removes the excuse:

*A carve-out quarter (the spin closed 2024-04-01), derived by subtraction.

INTERPRETATION: even on management’s own most favourable presentation, the operating margin has drifted down roughly 100–200bp over eight standalone quarters, and adjusted EPS has gone $6.70 → $6.11 → a guided $6.40–6.60. Even at the high end of the current guide, FY2026 adjusted EPS is below the FY2024 level. Two years post-spin, this company has produced zero adjusted earnings growth.

6.3 The GAAP → adjusted bridge, and which add-backs survive scrutiny

FACT: the add-backs are rising, not falling — 9.4% of revenue in FY2024, 12.9% in FY2025, 15.5% in Q1-2026. FY2025 GAAP pre-tax income ex-gain was $164M against adjusted pre-tax income of $1,324M; the add-backs equal 88% of adjusted pre-tax income, and only 27% of them ($312M of $1,160M) are non-cash amortization.

Item-by-item judgement:

• Amortization of acquired intangibles — accept, with a caveat. Standard convention. But it grows with every deal: the 10-K’s own schedule guides $361M in 2026 (up from $312M) because Acera added $440M of intangibles. Solventum spends 8.9% of sales on R&D and paid ~8× sales for Acera — it is visibly re-buying the technology it adds back.
• 3M spin-off and separation-related ($579M FY2025; $163M in Q1-2026 alone) — partially legitimate. These do have a defined end (TSA exits, ERP cutovers), but have now run three consecutive years and are the largest add-back. Note the 10-K’s own definition includes “profit mark-ups on transition service arrangements with 3M.” The mark-up disappears at TSA exit — the underlying function does not. Solventum must build and staff it. Not fully creditable to future earnings.
• Restructuring ($80M FY2025; $41M in Q1-2026 alone) — reject. “Solventum Way” ($90M total) closed in 2025 and was immediately succeeded in November 2025 by “Transform for the Future,” a four-year ~$500M pre-tax cost programme. Perpetual restructuring is an operating cost.
• Certain litigation-related ($51M FY2025; $14M Q1-2026) — reject. Principally Bair Hugger defence cost, which Solventum owns contractually and in perpetuity. A structural feature of the business.
• Acquisition costs ($12M) and the $82M net loss on debt extinguishment — accept.

Decomposition of the FY2025 $6.11:

INTERPRETATION: 55% of adjusted EPS ($3.34 of $6.11) is supported by excluding real cash spending. Removing only the add-backs rejected outright (restructuring + litigation) gives an honest FY2025 EPS of ~$5.55; haircutting half the separation add-back as well takes it to ~$4.28.

6.4 Cash flow — the weakest part of the story

FACT: FY2025 free cash flow was −$10M against guidance of $150–250M. Management stated on the Q4-2025 call that “adjusting for the P&F divestiture and separation costs, during 2025 free cash flow would have been approximately $1.0 billion.”

FACT: Q1-2026 free cash flow was −$273M versus −$80M a year earlier — cash burn more than tripled year-on-year while adjusted EPS grew 10.6%. The Q1-2026 drivers: accrued compensation −$151M, due to related parties −$100M, all-other operating −$94M, deferred taxes −$41M.

INTERPRETATION: this is the largest divergence between reported income and cash in the medtech peer set. Management’s long-range target is >80% conversion; FY2026 guides to ~$200M, or roughly 18%. The entire bull case is the assertion that a ~$1.0B gap closes in 2027. There is not yet a single quarter of cash evidence for it — the gap widened in Q1-2026.

One item that flatters FCF: the ~$207M Eagan headquarters was structured as a finance lease (recognised Q1-2026, term to 2046). Roughly $200M of real capital formation therefore appears in neither capex nor free cash flow. Separately, operating lease cost has quadrupled — $28M (FY2023) → $75M (FY2024) → $122M (FY2025) — as Solventum built a standalone footprint.

6.5 Balance sheet and leverage — the one unambiguously good story

FACT — the capital structure. February 2024: $6.9B senior notes plus $1.5B term loans = $8.4B principal, $8,303M net of issuance costs, essentially all remitted to 3M other than a ~$600M retained-cash target. In September 2025 Solventum tendered $1.9B of senior notes (the two longest, highest-coupon tranches preferentially killed — 6.00% '64 and 5.90% '54 — plus 5.45% '27 and 5.40% '29), prepaid $870M of the three-year term loan and retired the $200M eighteen-month facility: $3,070M of repayment, at a $94M gross extinguishment loss ($82M net of swap gains).

FACT — maturity ladder (principal, 12/31/25): 2026 nil · 2027 $460M · 2028 nil · 2029 $703M · 2030 nil · after 2030 $3,920M · total $5,083M. 77% matures after 2030. Only the $110M term loan floats (2.2% of debt). Weighted-average coupon ≈ 5.60%.

FACT — the interest tailwind is already spent. Interest expense, net: $367M (FY2024) → $347M (FY2025) → $51M in Q4-25 and $62M in Q1-26, a run-rate of ~$210–250M. Worth ~$100–120M pre-tax annually, roughly $0.46–0.55/share after tax — and it is already embedded in the FY2026 guide of $6.40–6.60.

FACT — the cash is in the wrong place. Of the $878M at 12/31/25, ~$800M was held by foreign subsidiaries and only ~$78M in the United States, with ~$1B of undistributed foreign earnings asserted indefinitely reinvested. Domestic buyback and debt-paydown capacity depends on domestic free cash flow, not the headline cash balance. Liquidity is otherwise ample: $2.0B undrawn revolver to 2029 and a $2.0B commercial-paper programme with nothing outstanding.

OPEN QUESTION: Solventum does not disclose its credit ratings in the 10-K — only a risk factor that a downgrade below investment grade would be harmful. S&P is understood to have assigned BBB− pre-spin and placed the company on CreditWatch positive after the P&F announcement; a subsequent upgrade could not be verified and is not relied on here.

6.6 Returns on capital — the whole argument in one table

Invested capital (financing side) = total equity + total debt − cash: $10,207M (12/31/24) → $9,206M (12/31/25); average $9,707M. Cross-checked from the asset side: total assets $14,294M − non-interest-bearing current liabilities $3,136M − cash $878M − non-debt long-term liabilities $1,074M = $9,206M ✓.

Goodwill $5,704M plus net acquired intangibles $2,592M = 58.0% of total assets and 163% of book equity.

FY2025 NOPAT under three definitions, at the disclosed 19.1% adjusted tax rate:

Tangible operating capital = PP&E + receivables + inventory − payables. ROIC.ai independently reports FY2025 ROIC of 5.42%, consistent with definition ©. A separate build using adjusted operating income and a debt-plus-equity denominator gives ~13.6%, consistent with (A) — the ~0.6pt difference is tax-rate and averaging convention, not a disagreement. Definitions matter more than the number here; the memo uses (B) as the owner-earnings base and cites the full range.

Supporting returns: ROE 38.9% GAAP (meaningless — gain-driven), 26.7% on adjusted net income, 4.0% on GAAP ex-gain. ROA 10.8% GAAP, 7.4% adjusted, 1.1% GAAP ex-gain.

INTERPRETATION — this is the crux. The spread between ~5–8% ROIC on the full capital base and ~27–48% on tangible operating capital is the Solventum story. The operating businesses are asset-light and earn extraordinary returns on the capital they actually employ. The $8.3B of goodwill and acquired intangibles is the price 3M paid over decades — Acelity/KCI at $6.7B in 2019 above all — and it is now Solventum’s carrying value. Buying SOLV at a premium to book capitalises 3M’s historic overpayment a second time. Tangible book value at 3/31/26 is −$3,154M, or −$18.18/share.

Peer cross-read (peer figures from company filings and aggregated fundamental data, re-struck to 2026-07-30 prices where possible):

INTERPRETATION: on returns and leverage Solventum is unremarkable — mid-pack, better-levered than most. On earnings quality it is the worst in the group after Baxter, and for a more troubling reason: BDX, ZBH, STE and MDT’s add-backs are dominated by non-cash amortization (72–100% of the wedge). Solventum’s are dominated by cash spending (only 27% amortization). Its adjusted number is the least cash-supported in the peer set, and the FCF-conversion row proves it.

6.7 Segment economics — HIS is the entire quality argument

FACT — HIS is the crown jewel. 18.1% of FY2025 consolidated sales but 30% of reportable segment profit at a 36.5% margin (up 360bp y/y and 360bp since FY2023). In Q1-2026, 17.7% of segment sales and 34% of segment profit at 38.1% (+500bp y/y). It is the only segment with expanding margins.

FACT — MedSurg is the problem. Margin has collapsed 1,080bp, from 23.9% (FY2023) to 13.1% (Q1-2026), on 62% of sales. The filings name the drivers: tariffs (~$55M FY2025, guided $100–120M FY2026), a full year of 3M master-supply-agreement mark-ups, higher logistics, and standalone stand-up cost. Cost of product purchased from 3M rose from $128M (FY2024) to $241M (FY2025); total 3M transition-agreement expense rose from $369M to $534M; total related-party P&L cost went $567M → $876M. These are rising, not rolling off.

FACT — the operating-leverage test fails. From FY2023 to FY2025, reportable segment revenue rose $280M (+3.9%) while reportable segment operating income fell $320M (−16.2%). Incremental margin is negative.

6.8 Quality of earnings — clean where it usually isn’t

Working capital is honest. DSO 46.2 → 45.3 → 46.8; DIO 96.2 → 100.4 → 103.8 (up ~8 days on ERP/distribution-centre transitions and safety stock); DPO 61.6 → 64.7. Cash conversion cycle ~81 days, essentially flat. Allowance for doubtful accounts $87M on $1,121M gross receivables (7.8%), unchanged. No channel-loading or receivable-stuffing signal.

No software-capitalisation game. All $4,785M of gross intangibles are acquisition-related; no capitalized internal-use software line appears. For a company with a $1.36B software segment that is a genuine positive — HIS expenses 100% of its development and still earns 38%.

SBC is honestly expensed — management does not add it back. But it is growing fast: $39M (FY2023) → $112M (FY2024) → $161M (FY2025, 1.9% of sales) → $51M in Q1-2026 (~$204M annualising, 2.5% of sales). The ~$200M SBC run-rate exceeds the $67M-per-quarter buyback pace, so net share count has been rising (diluted 172.7 → 173.7 → 175.3 → 175.5M, ~0.9%/yr).

Tax is not aggressive but is drifting up. GAAP ETR 19.3% (FY2023) → 20.9% (FY2024) → 9.2% (FY2025) — the collapse entirely the P&F gain, with a −10.0pt Cayman Islands benefit in the rate reconciliation. The adjusted rate was 18.1% (FY2024), 19.1% (FY2025), guided 19.5–20.5% (FY2026). Cash taxes $181M vs $244M.

Amortization is rising, not decaying: 4.5% of revenue (FY2023), 4.2% (FY2024), 3.7% (FY2025), with the 10-K’s own schedule guiding $361M in 2026 (~4.4%) off Acera. Scheduled: 2026 $361M · 2027 $356M · 2028 $351M · 2029 $313M · 2030 $208M · after-2030 $1,003M.

Pension/OPEB inherited from 3M is small: net liability $363M, expense $62M (FY2025). Not a thesis item.

6.9 Guidance and the track record since the spin

INTERPRETATION: the pattern is unambiguous — sales and adjusted EPS delivered or beaten; cash missed badly. That is exactly the pattern one expects if the add-backs understate the true cost of running the business.

Two modelling warnings. (1) Q2-2026 had not been reported as of 2026-07-31; the print is scheduled 2026-08-05. (2) Management disclosed ~70bp of Q2 volume pulled into Q1 and pre-announced a ~$100M advance-ordering benefit landing in Q2-2026 that reverses in H2, mostly Q3, ahead of the final ERP cutover. H1-2026 reported numbers will overstate the run-rate, and a Q2 beat must not be read as confirming the FY2026 margin bridge.

6.10 Verdict — Financial Quality

No — the economics have not improved with scale, and not on any measure actually observed.

Since carve-out, revenue has risen $128M while adjusted operating income has fallen $292M and adjusted EPS has gone from $6.70 to $6.11, with FY2026 guided still below the FY2024 level. Gross margin is down 380bp since FY2023 and SG&A/sales is up 900bp. Incremental operating margin over the post-spin window is negative. Two full years of standalone operation have produced cost, not leverage.

The business underneath is genuinely good, and precision matters here: ~26.6% return on tangible operating capital on an owner-earnings NOPAT, an HIS segment compounding at 38% margins and carrying a third of segment profit on a sixth of sales, low ~4.5% capex, a flat 81-day cash conversion cycle, clean receivables, no software-capitalisation or reserve games, and stock compensation honestly expensed inside the non-GAAP. The deleveraging is real — 3.8x to 2.4x, with 77% of principal maturing after 2030 at a ~5.6% fixed coupon.

But the reported earnings stream is the least cash-supported in the medtech peer group. Add-backs equal 88% of FY2025 adjusted pre-tax income, and only 27% of them are non-cash amortization; the rest is cash spent on separation, on a permanent cycle of restructuring programmes, and on litigation Solventum owns forever by contract. FY2025 adjusted net income of $1,070M converted to negative $10M of free cash flow, and the gap widened in Q1-2026. More than half of adjusted EPS — $3.34 of $6.11 — exists only because real cash spending is excluded from it.

So: high-quality earnings stream, or over-levered amortization-heavy carve-out whose “adjusted” numbers flatter reality? On today’s evidence, closer to the latter — though the leverage criticism is now stale (2.4x is fine) and the amortization criticism is the smaller half of the problem. The accurate charge is that Solventum’s adjusted earnings are cash-flattered, not amortization-flattered, which is the more serious sin. Whether that reverses becomes knowable in 2027. Everything in the bull case hinges on it, and there is not yet one quarter of evidence.

7. Capital Allocation

7.1 The separation balance sheet: a financing, not a capitalization

FACT. Essentially 100% of the $8.3B Solventum borrowed went straight to 3M, and 3M additionally kept $1.1B of net assets. 3M distributed 80.1% (138,340,315 shares) on 2024-04-01 and kept 34,369,190 shares (19.9%).

INTERPRETATION. This was a cash extraction dressed as a capital structure, set by 3M’s board before Solventum had an independent one. Roughly 4× adjusted EBITDA on a business then growing organically at 1.2%, with no dividend, ~$380M of capex and $349M of separation costs already running, is not a structure any independent board would have chosen. Its practical consequence was to make Solventum a forced seller within ten months of listing — and the fact that the forced sale landed in a hot bioprocessing M&A window is luck, not design. The $729M of cash interest paid in the first 24 months is the direct, permanent cost of 3M’s decision, borne by Solventum’s shareholders.

7.2 The P&F divestiture: the best decision management has made

Verdict on the divestiture: unambiguously value-creating. Solventum sold its lowest-margin, fastest-deteriorating, least-medtech asset — one whose segment operating income had just fallen 42% year-over-year — to a strategic buyer at roughly four to five times the multiple its own equity commands. That is textbook Greenwald/Marathon behaviour: exiting a business where you are sub-scale against Danaher, Sartorius, Repligen and Merck KGaA rather than feeding it capital.

Use of proceeds (FY2025 cash-flow statement, actual dollars):

Retiring 40-year 6.00% paper with divestiture cash is correct liability management; the $94M premium is what it costs to buy debt back above par, and is money well spent relative to carrying 6% coupons to 2064.

7.3 Buybacks: right authorization, right prices, tiny scale, wrong funding source

Three things are true at once. (i) The execution has been price-sensitive in the right direction — 51% of the quarter’s shares were bought in the cheapest month, and the tranche is up ~20%. (ii) The stated purpose is anti-dilution — the CFO, Q4-2025: “directionally, it is reasonable to think about the authorization as offsetting the impact of our stock-based comp dilution and holding that share count relatively flat” — which is share-count management, not value capture. (iii) Most importantly, Q1-2026 GAAP free cash flow was −$273M and total debt rose $45M in the same quarter. FY2026 GAAP FCF is guided at ~$200M against a $1B authorization. The buyback is currently balance-sheet-funded, not cash-flow-funded. Defensible for one transitional year; not a repeatable capital-return policy, and investors should not treat the authorization as a price floor.

Dividend: none, ever. With ~$5.1B of debt, ~$270M of 2026 net interest and ~$400–450M of capex, a dividend would be debt-financed. Not paying one is a point in management’s favour.

7.4 M&A: one deal, correctly shaped, fully priced

Acera Surgical (closed 2025-12-23, $776M total consideration; ~8× upfront / ~9.4× total EV/sales on ~$90M of estimated 2025 revenue) is ~90% goodwill and intangibles — there is no asset backing, and 8–9× sales is a full price. But it is the right shape of deal: adjacent to an existing call point, plugged into a sales force Solventum already pays for, ~5% of enterprise value, and small enough to be survivable if it disappoints. Contrast with the destructive alternative available to a newly independent company holding $4B of divestiture cash: a transformational deal. Management didn’t do that. Credit where due.

Forward portfolio pruning — explicitly signalled, not yet filed. The CEO, Q1-2026: “We see portfolio optimization as a perpetual lever for value creation… when we determine that someone else can offer more value for a business we divest… we will act decisively just like we did with the purification and filtration business.” Dental Solutions and HIS are the obvious candidates. No 8-K or filing confirms either. [OPEN QUESTION]

7.5 Reinvestment: the “3M starved it” story is not visible in R&D

FACT. R&D fell $36M (−4.6%) in absolute dollars in the first full year under new management; SG&A rose $298M. INTERPRETATION. Incremental post-spin spend has gone to standalone overhead, ERP, distribution-centre stand-up and payments to 3M — not to research. R&D intensity of 8.9% is nonetheless toward the upper end of large-cap medtech (roughly 6–9%), flattered by HIS software development running through R&D. The reinvestment case therefore rests on commercial-model change, not on R&D dollars.

7.6 Incentive alignment: the load-bearing weakness

FACT: there is no ROIC, ROE, ROTC or economic-profit metric anywhere in the AIP or the LTIP. INTERPRETATION: this is precisely the design the playbook flags as vanity — revenue with no capital requirement (50% of both plans), and adjusted EPS (30% of the PSU), the one metric a $3.0B debt paydown and a $1B buyback deliver automatically. Management is being paid for doing what the balance sheet compelled it to do.

The 2025 payout — and what it looked like before the Committee’s adjustments:

FACT. Each “actual” contains a discretionary Talent Committee add-back disclosed in the same proxy: +$234M to revenue, +$64M to adjusted operating income beyond the standard non-GAAP measure, and +$540M to free cash flow. FACT. Solventum’s GAAP free cash flow for FY2025 was negative $10M — and the 2026 proxy’s own performance-highlights box prints “Free Cash Flow ($10M)” on the same page that justifies a 120%-of-target FCF payout.

INTERPRETATION (arithmetic by straight-line interpolation between the proxy’s own threshold/target/max points). On unadjusted results the Business Performance Factor would have been roughly 76%, not 123% — a ~47-point swing bought with discretion. And the discretion compounds: the proxy states the FCF target was set low because “Free Cash Flow was expected to be impacted by separation costs” — and the Committee then added separation costs back to compute the actual. The same headwind was credited twice, once in a reduced target and once in an inflated result. The CEO’s individual modifier then took the 123% factor to 1.48× target.

Pay levels and skin in the game:

One-time separation-related awards to the five named executives totalled roughly $70.8M at target — including $44.7M for the CEO alone (hiring bonus, make-whole RSUs and cash, and $16.0M of inducement PSUs that pay 0–200%, worth $45.0M at maximum). Broad one-time “founders’ RSUs” were also granted to employees and non-employee directors in 2024.

Ownership guidelines are met largely by counting unvested RSUs. FACT (2026 proxy, as of 2026-03-19): the CEO owns 123,910 shares; all 18 current directors and executive officers together own 287,500 shares plus 125,730 acquirable — under 0.24% of shares outstanding, roughly $36M at $86.82. INTERPRETATION: the entire insider group has less capital at risk than the company’s quarterly SBC expense. The CEO’s ~$10.8M of owned stock sits against ~$20M of annual pay.

The compensation peer group — Danaher, Intuitive Surgical, Stryker, Medtronic and seventeen others — benchmarks an $8.3B-revenue, 2–3%-growth carve-out against companies several times its size and quality, which inflates the reference point structurally.

Shareholders have noticed:

7.7 Verdict — Capital Allocation

Capital deployment since the spin has been intelligent; the incentive system that governs it is not. The P&F sale is a genuine, quantifiable value creation; 79% of the proceeds retired 5.4–6.0% debt including the worst tranches; the one acquisition is small and on-strategy; there is correctly no dividend; and the buyback, while tiny, was executed at the right prices. Against that: a compensation plan with no return-on-capital metric anywhere, which tolerated a 123% bonus payout in a year of negative GAAP free cash flow by adding $540M of “compensation-purposes” adjustments to a metric whose target had already been lowered for the same costs, and which leaves an executive team owning less than a quarter of one percent of the company. The decisions have been better than the incentives deserve. That is not a durable state of affairs, and a 74% say-on-pay vote plus an activist at the door says the market agrees.

8. Changes and Headwinds — Last Two Years

8.1 The material-event timeline

Registration statements — nothing exotic. The S-4 (2024-11-15) is a routine A/B registered exchange of the $6.9B of 144A senior notes for identical registered notes — not a debt-for-equity exchange. The S-3ASR (2025-08-13) is an automatic shelf that enabled 3M’s resale two days later. No new equity has been issued to the public since the spin.

SEC staff correspondence — clean. The only two Corp Fin letters (2024-02-27 and 2024-03-13) concern redactions in Form 10 exhibits (the 3M supply/transition agreements); the staff subsequently wrote “We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements.” There are no accounting, revenue-recognition, segment, carve-out-allocation or non-GAAP comments in the file. For a newly public carve-out with pushed-down parent allocations, that is a genuinely clean record.

8.2 The insider read — 105 Form 4s parsed

The two facts that matter. (1) Zero code-S open-market sales by any Solventum officer or director across 27 months. The only S in the corpus is 3M’s. No named executive has sold a single share into a stock that has roughly doubled off its low. That removes the most common red flag. (2) One code-P purchase in the entire corpus: director Amy McBride Wendell, 1,475 shares at $68.03 on 2026-03-10. Total insider open-market buying since the spin: $100,344.

INSIDER VERDICT: NEUTRAL — and specifically not a bullish tell. The absence of discretionary selling is genuinely reassuring. But the officer-and-director group owns <0.24% of the company and nobody is putting personal money at risk. Read as “no negative signal,” not “conviction.”

3M’s residual stake — the overhang: 34,369,190 shares at spin, less 8,800,000 sold at $73.45 on 2025-08-15, leaves 25,569,190 shares (14.7%), worth ~$2,220M at $86.82. 3M has no voting power (it granted Solventum a proxy to vote its shares proportionally) but retains sole dispositive power, with a live S-3ASR shelf. It sold its first tranche at $73.45; the stock is now $86.82. [INTERPRETATION] Supply is most likely to arrive when the price is best, which is now.

8.3 Litigation and contingent liabilities — the 3M split, nailed down

INTERPRETATION — this is the memo’s most important tail risk and it is essentially unreserved. A company with $31M of total accrued litigation is the economic defendant in an 8,400-plaintiff MDL with bellwether trials scheduled in 2026, while management explicitly declines to estimate any range of loss above the recorded liability. The structure is asymmetric in the worst way: 3M is the named defendant; Solventum pays. A decade of litigation without a plaintiff verdict of scale is why the accrual is small and is the honest bull argument — the December-2021 first federal bellwether was a defence verdict, and Minnesota’s 61 state cases were resolved for 3M in 2019. But a bellwether loss in 2026 would be a genuinely binary event, and the market is not pricing it.

Second, under-appreciated: the PFAS indemnity cliff. 3M’s indemnity covered products “sold on the same basis… through 2025.” That expired seven months ago. From 2026 Solventum owns PFAS liability on every product it continues to sell containing third-party PFAS components — with no reserve, no quantification of affected revenue, and a supply-chain problem attached. This risk did not exist in this form in the FY2024 disclosure.

8.4 Verdict — Changes and Headwinds

On balance the last two years strengthen the balance sheet and weaken the earnings quality — and the newest developments cut both ways. Strengthening: the P&F sale and the deleveraging that followed; a competent CCO hire consolidating a fragmented commercial model; a small, on-strategy acquisition; a buyback authorization executed at good prices; and a demonstrably clean SEC comment-letter file. Weakening: two consecutive years of rising add-backs, a $260M free-cash-flow guidance miss, a second multi-year restructuring programme launched before the first was cold, tariffs doubling, MedSurg’s margin falling another 470bp, an incentive system that paid 123% on negative cash, a say-on-pay vote down 12 points, and a PFAS indemnity that quietly expired at the start of this year. The activist’s arrival is not a headwind so much as a symptom — and the single most consequential un-filed possibility in the name.

9. Risk Analysis

The risk profile is unusual for a 0.79-beta consumables business: the largest risks are not operational but structural and legal — a cash-conversion promise, an unreserved mass tort, a technology displacement with a dated catalyst, and a residual dependence on the former parent for both critical inputs and 14.7% of the float. That combination is why the valuation scenario dispersion is 3.1×, far wider than the beta implies.

10. Valuation Discussion — Embedded Expectations

No price target and no recommendation appear in this section. It establishes what must be true at the current price.

10.1 One price, three companies

Solventum’s valuation is not a debate about the multiple. It is a debate about the denominator, and the same $86.82 supports conclusions that differ by more than 50%.

Choose adjusted EPS and Solventum is an ordinary cheap-medtech name. Choose cash and it is the most expensive stock in its peer group by a factor of three to five. Nothing else in this section matters as much as which denominator you believe.

10.2 Comp set — fair on the multiple, expensive on the earnings behind it

All market caps and EVs re-struck at 2026-07-30 closes.

Forward adjusted P/E uses each company’s own published guidance or consensus, re-struck at the 2026-07-30 price. Where forward adjusted EPS could not be verified it is shown n/a rather than guessed. BAX’s multiple is event-distorted.

On the headline forward multiple SOLV is precisely mid-cohort — 13.2x, essentially on top of BDX (13.1x), above ZBH (11.2x), below MDT (14.4x) and GEHC (14.3x), far below STE (20.6x) and ALC (20.4x). Nothing in that row is a mispricing signal in either direction.

The signal is in the rows underneath. SOLV grows at 2–3% organic against BDX at 4–5%, MDT at 5.5–6% and STE at 7% — slower than every name it is priced alongside except the visibly broken ones. Its 1.33% guided free-cash-flow yield is the lowest in the table by a factor of three to the next-lowest (BAX at ~4.0%), and its trailing actual yield is negative; ZBH, two turns cheaper on adjusted EPS, pays an 11.4% cash coupon, and BDX at an identical multiple converts its adjusted earnings into cash essentially one-for-one. And no other name adjusts out perpetual restructuring and the defence cost of a mass tort it owns forever and a ~$650M/year separation run-rate whose own definition includes 3M profit mark-ups.

Verdict: fair on the multiple, expensive on the earnings behind it. At 18.5x GAAP EBITDA ex-gain, Solventum is the joint most expensive name here alongside a BAX whose number is a known broken-earnings artefact. Being priced in line with a faster-growing, fully cash-converting BDX is not a discount.

10.3 Sum-of-the-parts — the break-up is already in the price

Segment build (FY2025 continuing basis; non-amortisation D&A allocation is an ASSUMPTION — total FY2025 D&A $489M less $312M acquired-intangible amortisation = $177M):

A cross-check that validates the build and cuts against the bulls. FY2025 management-adjusted operating income was $1,709M. Segment EBIT including P&F’s $96M is $1,789M. The residual unallocated corporate cost on a management-adjusted basis is therefore only ~$80M — Solventum pushes essentially all overhead into the segments. That sounds break-up-friendly. It is the opposite: because only $80M sits unallocated, the entire $766M of FY2025 adjusted-out cash charges is corporate-level spending that a SOTP built on adjusted segment profit silently ignores. An honest break-up valuation must charge it back.

The FY2026 guide, decomposed. Total adjusted operating income of $8,150M × 21.25% = $1,732M, plus $80M unallocated = $1,812M of segment profit. Holding Dental at 25.0%, HIS at 38.0% and Other at 15.0%, MedSurg must run at 17.6% for the year — against 16.8% in FY2025 and 13.1% in Q1-2026. That is a ~450bp intra-year recovery in the segment carrying the entire $100–120M tariff bill. Because Q2-2026 will be flattered by the ~$100M advance-order pull-forward, H1 cannot settle this; Q3 can.

The SOTP bridge:

Multiple anchors, sourced. MedSurg is bracketed by BDX (11.2x), GEHC (12.1x), ZBH (10.1x) and BAX (~9.3x adjusted); 8.5–11.5x reflects a margin down 1,080bp since FY2023, the whole tariff line, and continuing purchases from 3M under mark-up-bearing supply agreements. Dental is bracketed by XRAY (8.7x), NVST (12.1x) and ALGN (14.1x); Solventum Dental’s 27.8% EBITDA margin beats all three, supporting the upper half, while China VBP 2.0 argues the other way. HIS is bracketed by Waystar (12.9x EBITDA / 4.62x sales, growing 9–10%) at the top and Health Catalyst (10.4x / 0.71x sales) / Evolent (14.5x / 0.64x sales) at the bottom.

The three deductions are judgements, not computations, and their fragility must be disclosed. (i) Stranded corporate: a break-up does not eliminate the ~$650M/year separation run-rate or the new four-year ~$500M restructuring programme, and it adds a second set of public-company costs — $100M/$150M/$200M of permanent stranded overhead capitalised at ~10x. (ii) Litigation: $31M accrued against 8,400+ suits going to trial, and an unreserved, unquantified PFAS exposure live since 2026-01-01. (iii) TMA: the 10-K itself says the §355(e) indemnity may discourage a change of control. Combined the deductions are $1.8B–$4.0B = $10–$23/share. A reader who rejects them entirely adds ~$17/share to the base case, putting SOTP at ~$96 — modestly above spot. That is the most contestable part of this analysis and it is stated rather than buried.

The finding: at mid-range public-comp multiples the sum of the parts is below the current enterprise value. Only the bull SOTP — HIS at 15x EBITDA / 5.9x sales, a premium to a faster-growing and far better-disclosed Waystar, plus MedSurg at 11.5x, plus minimal stranded cost, plus a benign litigation outcome — produces a material gain. The market is already paying a break-up price for a break-up that has not been announced.

And HIS is where the whole thing is decided:

A $32/share swing — 37% of the price — on a segment that is 17% of revenue and discloses no RPO, no backlog, no net revenue retention, no renewal rate and no contract duration, whose 10-K describes deferred revenue as relating to one-year software license contracts, that won zero 2026 Best-in-KLAS awards across six adjacent categories, and that faces Epic launching fully autonomous ED and radiology coding in November 2026. An acquirer diligencing HIS would demand precisely the disclosures Solventum does not make. In their absence, 8x is not punitive.

The counterweight, stated fairly: HIS’s 36–38% margin is struck with zero capitalised internal-use software, and the APR-DRG grouper embedded by name and version number in state Medicaid regulation is a real annuity. Both things are true.

10.4 Reverse-DCF — what $86.82 requires

WACC. Risk-free 4.3%, ERP 5.0%, beta 0.79 → cost of equity 8.25%; also run at 8.5% and 9.0%, because that beta is measured over only ~587 trading days whose left tail is a distressed de-rating and almost certainly understates the risk of an unreserved mass tort and an unproven cash story. Cost of debt ~5.60% weighted-average coupon, after-tax 4.48%. At market weights (74.8% equity / 25.2% debt): WACC 7.30% / 7.49% / 7.86% — base 7.5%, range 7.0–8.5%. Tax 20%, capex 4.5% of sales, non-amortisation D&A ~$180M, working capital 5% of incremental revenue. [ASSUMPTION throughout]

The valuation flips from cheap to full on the add-back question alone. Credit management in full and the market wants 1.4% forever against a 4–5% long-range plan — genuinely undemanding, and this is the strongest quantitative form of the bull case. Charge back the cash items rejected in the earnings-quality discussion above and it wants 2.2%. Charge back half the separation cost — the right treatment if TSA exit merely moves the expense from 3M’s invoice to Solventum’s payroll — and the market wants 3.5% perpetual growth from a business guiding 2–3% organic that has posted a negative incremental operating margin for two years.

On actual cash (unlevered FCF = levered FCF + after-tax interest of ~$184M):

At the guided $200M the market is embedding 5.5% perpetual growth — an assumption nobody is actually making. The only coherent reading: the market is not valuing today’s cash. It is valuing the 2027 convergence.

Is that convergence already paid for in full? Yes — and this is the spine of the report. Solving EV = uFCF/(WACC − g) for the required levered free cash flow ($M):

Across the entire plausible box, $86.82 requires levered free cash flow of roughly $700M–$1,000M — against $200M guided for FY2026, −$10M delivered in FY2025 and −$273M in Q1-2026. That is a 3.5x to 5x increase within about two years, with zero quarters of supporting evidence.

Cross-check against management’s own plan: >80% conversion on ~$1.15B of adjusted net income = >$920M. Management’s long-range plan delivers almost exactly what the current price requires — and no more. There is no margin of safety for execution risk embedded anywhere in this price.

Capitalise the gap directly: $800M/year at a 7.5% WACC and 1.5% terminal growth is worth $13,333M of enterprise value — 68% of the $19,585M EV, or ~$77 of the $86.82 share price. Put plainly on the yield ladder: a buyer at $86.82 accepts a 1.33% cash yield today in exchange for the assertion that it becomes 5.3–6.6% in 2027.

What the market is underwriting correctly: the deleveraging is real and the ~$100–120M/year pre-tax interest saving is banked; HIS is a scarce, high-margin, regulation-embedded asset; adjusted-EPS guidance has been reliable; and the operating businesses genuinely earn ~26.6% on tangible operating capital.

What it may be underwriting incorrectly: that the ~$800M gap closes on schedule when it widened in Q1-2026; that the separation add-back is transitory when its own definition includes 3M TSA profit mark-ups whose underlying function transfers to Solventum; that MedSurg recovers ~450bp within FY2026; that a break-up creates value from here when the base SOTP does not; and that $31M is an adequate accrual against 8,400+ claims going to trial.

10.5 Scenarios to FY2028

Bear includes a $750M incremental Bair Hugger EV deduction. Probability-weighted ~$98/share = +12.7% versus $86.82, or roughly +4.9% per year over 2.5 years — below the ~8.25% cost of equity implied by the same beta used in the DCF.

Bear events: an adverse Bair Hugger bellwether verdict in 2026 establishing a settlement benchmark against a $31M accrual; Epic’s November-2026 launch takes HIS growth to zero and begins compressing the 38% margin; tariffs stay at $120M and MedSurg fails to clear 15%; the convergence slips to 2028 and “Transform for the Future” is extended. Base events: 2.5–3% organic, margin grinds toward but short of the 23–25% plan, FCF converges partially to ~$900M — which is, not coincidentally, exactly what the reverse-DCF says the current price requires. The base case is what is already priced. Bull events: the activist prevails and HIS is separated or sold at a strategic multiple; the ~$650M separation run-rate genuinely rolls off in 2027; MedSurg recovers as tariffs are mitigated and 3M supply agreements are exited; the $1.0B authorisation is used at scale rather than merely offsetting a ~$200M SBC run-rate.

Sensitivity (FY2028 equity $/share; net debt $4,600M, 172M shares):

The dispersion — $46 to $143, a 3.1x range — is extraordinarily wide for a 0.79-beta defensive consumables business, and it is wide for identifiable reasons: an unreserved mass tort, a dated competitive threat to the profit engine, and a cash-flow story with no supporting evidence.

10.6 Own-history percentiles — read P/S, discard P/E, understand why P/B disagrees

AZI valuation_index, 2026-07-30: P/S 1.84 at the 99.7th percentile; P/B 3.07 at the 46.7th; P/E 10.63 at the 49.7th; composite 65.4; n ≈ 587 trading days.

Discard the P/E percentile outright. TTM GAAP diluted EPS of $8.17 contains $7.97/share of after-tax P&F gain. Ex-gain, GAAP EPS is ~$0.20. A percentile built on that denominator measures nothing.

Why P/S and P/B disagree. Both denominators were damaged by the same event, in opposite directions. Book equity went from $2,959M (12/31/24) to $5,049M (12/31/25) — a 71% jump driven overwhelmingly by the $1,397M after-tax gain retained in equity. P/B therefore fell mechanically as the “B” inflated. And P/B is measuring price against an accounting artefact regardless: goodwill plus intangibles equal 163% of book equity, and tangible book value is −$18.18/share. A 3.07x P/B against an equity base more than fully composed of inherited goodwill is a statement about 3M’s M&A history, not about Solventum’s valuation.

Revenue is stable, uninterrupted by one-time items and unaffected by the gain. P/S is the only clean own-history read, and it says SOLV has essentially never been more expensive on sales in its public life.

The caveat that must travel with it. A ~2.3-year window is shallow, and it opens with the post-spin distressed de-rating. A percentile whose left tail is a forced-selling event will overstate how “expensive” the subsequent recovery looks. So the honest formulation is not “SOLV has never been more expensive,” but: the stock has round-tripped from a distressed spin discount to the richest price-to-sales it has ever supported, while adjusted EPS went $6.70 → $6.11 → a guided $6.40–6.60 and free cash flow went $805M → −$10M → a guided $200M. Multiple up, earnings flat, cash down. The 65.4 composite should not be used; it averages one clean signal with two corrupted ones.

10.7 Verdict — Valuation

The price embeds management’s full long-range plan and nothing worse. On adjusted earnings the stock is mid-cohort and the implied perpetual growth is undemanding; on cash it is the most expensive name in its peer group; on a sum-of-the-parts it is already at or slightly above what a break-up on mid-range comps would fetch. The three readings reconcile in one sentence: the market has already given Solventum credit for the 2027 free-cash-flow convergence, for a benign litigation outcome, and for a strategic separation of HIS — none of which has yet occurred, and one of which (the convergence) moved backwards in the most recent quarter.

11. Variant Perception

11.1 Consensus belief

[INTERPRETATION — inferred from the guide, the activist campaign, the sell-side action and the tape; ROIC.ai returned no news or estimate distribution for SOLV over a 60-day window, so no surveyed target distribution was obtainable. This is an inference, not a survey.]

“The self-help story is working.” Two years of separation pain are ending; the balance sheet is fixed at 2.4x; adjusted EPS is guided toward the high end; an activist is forcing overhead cuts and a break-up that will surface a hidden HIS jewel; and free cash flow snaps back to ~$1B in 2027. At 13x forward adjusted EPS that is cheap. The tape agrees — an all-time closing high of $88.55 on 2026-07-29, EMAs fully stacked, and a UBS upgrade to Buy on 2026-07-28.

11.2 The factor and positioning read

The empirical positioning evidence contradicts the simple “momentum name” reading. In the Base + Sector + Industry model (2026-07-30, R² 0.380, 587-day window, 39 active factors), betas read within that model only:

The Quality × Momentum cross is the inverse of the classic warning setup — the danger signal is high Momentum riding negative Quality; SOLV is positive Quality (+0.31) riding negative Momentum (−0.25). The sign structure is robust across models. The more awkward datum is Value at essentially zero: SOLV is neither a momentum name nor a cheap name in the cross-section. It sits in factor no-man’s-land — exactly what one expects of a stock priced off corporate actions rather than style. Confirmed directly: idiosyncratic volatility is 22.24% against 1-year total volatility of 29.68%, so 56% of variance is stock-specific, and model R² is only 0.356.

The 12-month return was earned against the factor profile, not with it. Over 252 days the Medical Devices industry factor returned −14.1% — SOLV’s largest non-market industry loading was the worst-performing industry factor of the year — while the Health Care sector factor returned +11.9%. Momentum returned +13.1% into a −0.247 loading, another drag. SOLV’s +18.96% is therefore almost entirely a corporate-action story: Thermo Fisher, deleveraging, the buyback, Acera, Trian.

Regime. Over the trailing 21 days Value +6.2% (z+1.99) and LowVolatility +6.0% (z+1.76) are near-extreme winners, while Momentum −4.8% (z−1.76), Quality −4.8% (z−1.77) and Growth −3.9% (z−1.57) are being sold. [INTERPRETATION, regime-caveated] A low-beta healthcare name is in a supportive regime, but fresh momentum breakouts are in a hostile one.

The Sharpe divergence is the tell. De-annualized and reconciled to the price CSV: m3 +28.89% period return (Sharpe 5.21, max DD −10.79%) against y1 +18.96% (Sharpe 0.57, max DD −27.46%) at essentially unchanged volatility. That is the arithmetic signature of a re-rating compressed into a short window, not of a durably better risk/return profile — the quarter borrowed return from the forward distribution.

Comp-set cross-check: the market does not classify SOLV as BDX/BAX/ZBH/STE/MDT. Factor-similar peers are COO (0.869), COWZ (0.865), DSTL (0.865), ONEV (0.862), ALGN (0.862), MOAT (0.861), VFLO (0.857), then Hyatt, RLJ Lodging, RPM, Spectrum Brands and NVST. Not one of the fundamental comps appears in the top 20. The surrounding wall is free-cash-flow / cash-cow / low-vol / wide-moat ETFs plus levered cyclicals — the common thread being a levered, mean-reverting recovery return stream, not an industry. That corroborates “special situation with a healthcare cash flow attached” over “defensive medtech.”

11.3 Strongest bull case, stated at its best

An $8.2B-revenue, asset-light franchise earning ~26.6% on tangible operating capital, trading at 13.2x the high end of its own guide, with the market embedding only ~1.4% perpetual growth on management’s numbers. Three things converge at once: ~$650M/year of separation cost has a defined end (final ERP cutover in 2026); the interest bill has already fallen ~$120M/year; and an activist with a real stake is forcing the portfolio simplification management would not do alone. Inside it sits HIS — 17% of sales, 30% of segment profit, 36–38% margins struck with zero capitalised software, with a grouper written by name and version number into state Medicaid regulation — a scarce asset worth $6–8B against a $19.6B whole-company EV. When free cash flow converges on adjusted net income in 2027, a 1.3% cash yield becomes 6–7% and the stock re-rates on cash rather than story. The insider record supports it: zero discretionary sales by any officer or director in 27 months.

11.4 Strongest bear case, stated at its best

You are paying an all-time-high price-to-sales multiple — the 99.7th percentile of the company’s own history — for a business that in two public years grew revenue $128M while adjusted operating income fell $292M, whose adjusted EPS is still below FY2024, and which converted $1,070M of adjusted net income into negative $10M of free cash flow. The entire valuation rests on an ~$800M convergence with zero quarters of evidence — the gap widened in Q1-2026 — and that convergence is worth ~68% of the enterprise value. The “adjusted” number that makes it look cheap is 88% add-backs, only 27% non-cash; strip the perpetual restructuring and the litigation Solventum owns forever and it is 15.6x; strip half the separation cost and it is 20x. Meanwhile the profit engine faces Epic launching autonomous coding in November 2026 against a segment that discloses no retention and won zero Best-in-KLAS awards; MedSurg must recover 450bp this year after printing 13.1%; $31M is accrued against 8,400+ suits going to trial; a 14.7% former-parent stake sits on a live shelf; and the 3M supply agreements behind ~36% of revenue are a rented barrier, not an owned one. And the break-up everyone is waiting for values the company below today’s price on mid-range multiples.

11.5 The assumptions that actually matter

1. Does free cash flow converge, and when? The price requires $700M–$1,000M; 2025 delivered −$10M. Load-bearing for both sides; everything else is second order.
2. Is the separation add-back transitory, or does the cost transfer from 3M’s invoice to Solventum’s payroll? ~$650M/year — $2.54 of the $6.11 FY2025 adjusted EPS.
3. Does HIS hold growth and its 38% margin through Epic’s November-2026 launch? 30% of segment profit; $6.6B of the base SOTP; a $32/share swing on the exit multiple alone.
4. Does MedSurg recover from 13.1% toward 17–18%, or is the 1,080bp collapse structural?
5. Is $31M adequate against Bair Hugger — and what is the newly-live PFAS exposure now that 3M’s indemnity has lapsed?

11.6 Verdict — Variant Perception

Consensus is not wrong about the direction; it is wrong about how much of the direction is already paid for. The variant perception available here is not “the turnaround will fail” — the turnaround is visibly working on revenue and adjusted EPS. It is that the cash never showed up, the market re-rated anyway, and the price now discounts a convergence, a benign verdict and a break-up simultaneously. The positioning evidence supports the framing: this is not a crowded momentum trade being chased by trend followers — SOLV loads negative on momentum, sits at zero on value, and derives 56% of its variance from stock-specific events. It is a corporate-action stock that has just been marked to the optimistic end of its own event distribution, three sessions before an unprinted quarter, on a sell-side rating change rather than a disclosure.

12. Fact vs. Interpretation

13. Open Questions

1. What are the terms and remaining duration of the 3M master supply agreements covering ~$3bn (36%) of revenue — and what is the cost of insourcing or reformulating the ~$2bn (24%) dependent on a 3M-proprietary process? This is the single largest un-priced structural exposure in the name.
2. What is Solventum’s insurance tower for Bair Hugger, and how much of the exposure is genuinely “uninsured”? The 10-K states the indemnity covers uninsured liabilities but discloses no coverage limits.
3. What is Solventum’s skin-substitute / Acera exposure to the CY2026 CMS reimbursement reset? Two direct competitors have disclosed and quantified a material headwind; Solventum has disclosed nothing.
4. What is the revenue split inside HIS between the declining clinician-productivity line, the contested CAC/CDI/autonomous-coding core, and the APR-DRG grouper annuity? Without it, the segment cannot be valued with confidence — and it drives a $32/share swing.
5. What are HIS’s remaining performance obligations, contract durations, renewal rates and net revenue retention? None is disclosed. Every switching-cost claim in the name is currently unfalsifiable from the filings.
6. How many SKUs still contain third-party PFAS components and what revenue do they represent now that 3M’s indemnity has lapsed and 3M has stopped supplying them?
7. What were cash taxes paid on the $1.5B P&F gain? Not broken out; management referenced “tax payments related to the P&F divestiture” as a Q1-2026 cash drag.
8. Is a strategic review of HIS or Dental actually underway? Management has hinted at post-§355(e) flexibility; no 8-K confirms anything.
9. What are Solventum’s current credit ratings? Not disclosed in the 10-K.
10. What explains the +10% move across 2026-07-27 to 2026-07-29 beyond the UBS upgrade — and does the market know something about the 2026-08-05 print that this report does not?
11. What is the vitality index, precisely? The metric is undefined in any filing, and management has given two mutually inconsistent framings of the same claim.

14. What Must Be True

14.1 For the bull case — with falsification tests

14.2 For the bear case — with falsification tests

The two tests that settle the debate fastest are B1/R1 (free cash flow) and B3 (MedSurg’s Q3-2026 margin). Both report within roughly six months of this memo, and neither can be obscured by the H1 pull-forward. B4/R3 — Epic’s launch and the two quarters around it — settles the more consequential question, and reports between February and May 2027.

15. Source Appendix

The full source appendix, listing every filing, transcript, dataset and third-party source cited in this note, appears as Appendix B below. Primary sources are Solventum’s SEC filings (2 x 10-K, 7 x 10-Q, 30 x 8-K, 2 x DEF 14A, 105 x Form 4, the Form 10 information statement and the SEC staff correspondence file), the Q4-2025 and Q1-2026 earnings-call transcripts, public price and valuation-percentile data, a public factor model, an aggregated fundamentals feed, and named third-party industry and regulatory sources.

Sections 1–15 carry no recommendation and no price target; the Claude's Take block at the head of this note is a clearly labeled exception. General information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Solventum Corporation (NYSE: SOLV) — 2026-07-31

Supplemental to the main note. Where a question does not map to Solventum’s business model, the correct analog is given rather than a forced answer.

General

What thoughtful questions have other investors asked about this company?

The most substantive external challenge on the record is Trian Fund Management’s open letter and slide deck of 2026-04-30, holding ~7.09 million shares (~4.1%). Its three questions are the right ones: (i) why does an $8.3B-revenue company that was profitable inside 3M carry a cost structure that has risen since independence — Trian’s framing is that the spin “has maximized executive compensation, not shareholder value”; (ii) why hold three businesses with no shared customer, channel, manufacturing or R&D platform, and specifically why is Health Information Systems — a 38%-margin software asset — inside a wound-care and dental-materials company; and (iii) why was $0 of the ~$3.9B of divestiture proceeds returned to shareholders in 2025.

Three further questions recur in the disclosure record and on the calls, and none has been satisfactorily answered:

• “Where is the cash?” — the FY2025 free-cash-flow miss (−$10M against $150–250M guided) was the single largest credibility event since the spin and preceded a 27.5% drawdown.
• “What are the actual HIS contract terms?” — analysts have pressed on switching costs; management answers with “pretty long contracts, multiple-year contracts” while the 10-K describes deferred revenue as relating to one-year software license contracts, and no RPO, backlog, renewal rate or net revenue retention is published.
• “What happens to Bair Hugger?” — Solventum indemnifies 3M, manages the litigation and funds the defence across more than 8,400 US suits, against $31M of total accrued litigation, with bellwether trials anticipated in 2026 and an explicit statement that no range of loss above the accrual can be estimated.

Shareholders have voted their answer: say-on-pay support fell from 85.9% (2025) to 74.2% (2026).

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither — they are at a structural trough of Solventum’s own making. GAAP operating margin ex-divestiture-gain has fallen 23.0% → 20.8% → 20.0% → 12.6% → 7.6% (FY2021–FY2025) and 4.0% in Q1-2026. Adjusted operating margin has gone ~24.4% (FY2023 carve-out) → 22.0% → 20.5% → 19.5% (Q1-2026). This is not the end-market cycle; it is separation cost, 3M supply mark-ups, tariffs and standalone overhead. The relevant observation is that management’s own 23–25% long-range margin target is a return to the FY2023 carve-out level, not an advance beyond it — an implicit admission that the trough is self-inflicted and recoverable rather than cyclical.

Driven by the external environment or internal actions? Overwhelmingly internal, with two genuine external drags. Internal: ~$579M (FY2025) of separation cost, $534M of payments to 3M under transition agreements, $876M of total related-party P&L cost, a ~$500M four-year restructuring programme, and a deliberate ~100bp SKU-rationalisation revenue drag. External: tariffs ($55M FY2025 → $100–120M guided FY2026) and a genuine decline in US surgical procedure volumes (HCA same-facility inpatient surgeries −0.3% then −2.3%; outpatient −1.7% then −3.4%).

How stable are revenues? Very. Revenue moved $8,171M → $8,130M → $8,197M → $8,254M → $8,325M across 2021–2025 — a four-year CAGR of +0.5%, with a maximum peak-to-trough deviation under 1%. That stability is the good news and the bad news in the same number: the business is non-discretionary and reorder-driven (no customer above 10% of revenue in any of 2023–2025), and it does not grow. Roughly 76% of revenue is product, almost all of it consumable; 16% is HIS software with $621M of unearned revenue; 7% is NPWT rental.

Outlook for products/services? Bifurcated, and the memo’s central structural point. HIS accelerating (+1.6% → +4.0% → +4.7%) with margins expanding 33.0% → 36.5% → 38.1%. MedSurg decelerating in its largest line (IPSS +4.5% FY2025 → +0.6% Q1-2026) with margin down 1,080bp since FY2023. Dental recovering off a weak base (+3.3%, +3.4%), though management characterises much of it as backorder catch-up. Clinician productivity (M*Modal) is in guided double-digit decline.

How big will this market be — growing, shrinking, domestic or international? Solventum’s own Form 10 sizing: MedSurg ~$26B growing 3–5%; Dental ~$17B growing 4–6%; HIS ~$9B growing 6–8%. On those numbers Solventum under-grew every one of its markets in every period since the spin. Directionally: sterilization assurance and payer-friction-driven RCM are growing; advanced wound care is growing at the device/bioactive end and stagnating at the dressing end; surgical consumables face declining case volumes; dental has under-grown the rest of US healthcare consumption by ~13 percentage points in five years; and skin substitutes just had a $10bn Medicare pool reset by the CY2026 Physician Fee Schedule. Mix is 56% US / 44% international, and international is currently the weaker half — Q1-2026 organic was +4.4% US against −1.1% international.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More, in three of five markets. Advanced wound care has new entrants (the FY2025 10-K added Medaxis to the named competitor list) and expired NPWT patents. Tapes, drapes and electrodes are structurally commoditised with a long Chinese tail, and the EU MDR simplification proposal of 2025-12-16 — estimated to save >€3.3bn a year — lowers a fixed-cost barrier that previously favoured large-portfolio incumbents. Healthcare coding is the most contested: $14.2bn of 2025 healthcare-AI venture funding, Epic launching autonomous ED/radiology coding in November 2026, and Solventum winning zero 2026 Best in KLAS awards across six adjacent categories. Less competitive: dental products, where capital is visibly exiting (Dentsply took a $598M net loss, $650M of impairments and cancelled its dividend), and sterilization assurance, which is concentrated and regulation-protected.

How profitable is the business (ROIC, ROE)? Definition-dependent, and the range is the finding:

ROE: 38.9% GAAP (meaningless — gain-driven), 26.7% on adjusted net income, 4.0% on GAAP ex-gain. The spread between ~5–8% on the full capital base and ~27–48% on tangible operating capital is the whole story: the operating businesses are excellent; the capital base includes $8.3B of goodwill and intangibles representing 3M’s historic purchase price (Acelity/KCI at $6.7B in 2019 above all). Tangible book value is −$18.18 per share.

How profitable is the industry — how many competitors, what barriers to entry? Poorly, and this is the decisive cross-section. Of Solventum’s named competitive set — BDX 5.9%, Smith+Nephew 7.5%, ConvaTec 9.5%, Steris 9.2%, Align 10.0%, Envista 1.4%, Mesa 2.9%, Dentsply n/m (net loss) — not one clears 11% ROIC. Greenwald’s threshold for evidenced competitive advantage is a sustained 15–25%. Competitor counts run from three or four (sterilization assurance) to the nine Solventum itself names in infection prevention and surgical solutions — and Solventum’s own Form 10 language for that segment concedes “a fiercely competitive pricing environment.”

Can the business be easily understood? The three segments individually, yes. The consolidated entity, no — and that is a real analytical cost. GAAP results are distorted by a $1,549M divestiture gain; adjusted results by add-backs equal to 88% of adjusted pre-tax income; segment results by an unallocated corporate line of only ~$80M that leaves $766M of adjusted-out cash charges sitting outside any segment. Three simple businesses inside one hard-to-read holding company.

Can it be undermined by foreign low-cost labour? In part, and it already is. Tapes, wraps, drapes, electrodes and basic surgical supplies face a long low-cost tail — precisely the SKUs the rationalisation programme is exiting (a ~100bp revenue drag in 2026, “the majority” in infection prevention and surgical solutions). Protected from it: HIS (US regulatory and workflow product), sterilization assurance (validated process, audited records), Tegaderm CHG (sole FDA clearance), NPWT (rental base plus home-care reimbursement infrastructure), and dental restoratives (handling-characteristic switching costs).

Do brands matter? In three places, genuinely. Littmann is a real consumer-style brand bought by individual clinicians and transferred intergenerationally through nursing and medical schools — and it is economically immaterial (~26% of a ~$663M global market; the entire world stethoscope market is roughly a third the size of Solventum’s wound-care line). Filtek/RelyX carry specification habit in dental restoratives. Bair Hugger is a category-defining name attached to an 8,400-plaintiff mass tort — a franchise wearing a liability. Elsewhere the brand does not reach the economic buyer, because in the US “the majority of our sales go through distribution” into GPO-mediated purchasing decisions.

What is the nature of competition? Four distinct games. (1) Protocol and formulary competition — Tegaderm CHG inside CLABSI-prevention bundles, where the decision is clinical governance, not purchasing. (2) Validated-process competition — Attest, where switching triggers revalidation under AAMI/ISO and Joint Commission audit. (3) Tendered price competition — the commodity tail, where GPOs and IDNs aggregate demand to strip margin. (4) Technology-displacement competition — HIS, where the incumbent’s rules-and-workflow franchise is being attacked by AI-native products and by the EHR vendor that already sits inside 57% of US beds.

Customers’ switching costs? Real, narrow, and asymmetric. Highest: the APR-DRG grouper (embedded by name and version number in Mississippi, South Carolina, Wisconsin, Florida and — new in July 2025 — Missouri Medicaid regulation; displacing it requires amending state regulations, re-deriving weights and re-running budget neutrality). High: Attest (revalidation), Tegaderm CHG (protocol re-approval and re-education), NPWT (rental base plus home-care reimbursement plumbing), 360 Encompass (coder workflow). Moderate: dental restoratives (handling characteristics, aesthetic-outcome risk on live patients). None: tapes, drapes, electrodes, basic surgical supplies. The critical insight is that autonomous coding is self-cannibalizing to the strongest software switching cost — management’s own pitch is “eliminating FTE cost infrastructure,” i.e. removing the coders in whose workflow the lock resides.

Financial Condition & Balance Sheet

Assets not fully recognised on the balance sheet? Several, and they are the good news. The APR-DRG grouper and classification methodologies — developed with CMS over decades and written into state Medicaid regulation — carry essentially no separable book value; the same is true of the ~1 million+ proprietary coding rules. All internally developed software is expensed (every dollar of the $4,785M gross intangible balance is acquisition-related; there is no capitalised internal-use software line), so HIS’s 36–38% margin is struck after fully expensing its own development. Clinical evidence — >2,000 peer-reviewed NPWT publications and a company-sponsored Prevena RCT — is an unrecognised barrier. The Tegaderm CHG FDA clearance as the only cleared transparent CHG dressing has no carrying value.

Off-balance-sheet liabilities? Yes, and they are the memo’s most important tail risk.

• Bair Hugger: more than 8,400 US lawsuits (the Q1-2026 10-Q cites more than 8,500), plus a Canadian putative class action, eight state cases and a Minnesota economic-damages putative class. Solventum indemnifies 3M for uninsured liabilities, manages the litigation and pays the legal expenses. Total company-wide accrued litigation is $31M, described as “not material,” with an explicit statement that no possible loss or range in excess of the recorded liability can be estimated. Bellwether and state trials anticipated in 2026.
• PFAS: 3M’s indemnity covered pre-spin liabilities and products sold on the same basis only through 2025 — it expired 2025-12-31, and 3M ceased supplying PFAS-containing components at the same date. Solventum continues to use third-party fluoropolymers (o-rings, gaskets and seals, NPWT canister membranes, adhesive-dressing release liners, circuit boards, lithium-ion batteries). No reserve is disclosed and the affected revenue is not quantified.
• Tax Matters Agreement: Solventum indemnifies 3M if the spin loses tax-free treatment, including under §355(e) if an acquisition or issuance of Solventum stock triggers it. The 10-K states this “might discourage, delay or prevent a change of control that Solventum shareholders may consider favorable.” Unquantified.
• Supply concentration: 3M is sole source for chemical materials behind ~$3bn (36%) of revenue, including one material with a 3M-proprietary process behind ~$2bn (24%).
• Smaller: ~$330M of unconditional purchase obligations over five years; $82M of bank guarantees and surety bonds; up to $75M payable to Thermo Fisher on a Water Business sale ($64M accrued); an Acera milestone up to $125M by 2030 ($80M accrued); operating lease cost that has quadrupled ($28M → $75M → $122M); and the ~$207M Eagan headquarters structured as a finance lease, so roughly $200M of real capital formation appears in neither capex nor free cash flow.
• Not an exposure: Combat Arms earplugs (3M’s Aearo business, never part of Health Care) appears nowhere in Solventum’s contingencies note or risk factors.

How conservative is the accounting? Conservative in the places that usually aren’t, aggressive only in the non-GAAP presentation. Clean: no capitalised internal-use software; stock-based compensation honestly expensed and not added back; working capital stable (DSO 46.2 → 45.3 → 46.8; cash conversion cycle ~81 days, flat); allowance for doubtful accounts unchanged at 7.8% of gross receivables; no channel-loading signal; PwC ratified at 99.7% in both proxy years; and — notably for a newly public carve-out with pushed-down parent allocations — the entire SEC staff correspondence file contains no accounting, revenue-recognition, segment or non-GAAP comments, only two 2024 letters about redactions in Form 10 exhibits, closed with the staff concluding its assessment. The 2026-07-16 Chief Accounting Officer change is a four-month-noticed retirement with a named successor, no restatement, no disagreement disclosure and no auditor change.

The aggression is entirely in the adjusted presentation: add-backs equal 12.9% of FY2025 revenue (15.5% annualised in Q1-2026) and 88% of adjusted pre-tax income, of which only 27% is non-cash amortization. Perpetual restructuring (“Transform for the Future,” a ~$500M four-year programme launched in November 2025 immediately after the $90M “Solventum Way” closed) and Bair Hugger defence costs Solventum owns forever by contract should not be excluded. On that basis, honest FY2025 EPS is ~$5.55 against a reported adjusted $6.11 — or ~$4.28 if half the separation add-back is also charged back.

How CapEx-hungry is the business? Structurally light, transitionally heavy. Capex is 3.5% of sales (FY2023) → 4.6% → 4.6% → 4.2% (Q1-2026), against net PP&E of only $1,326M on $14.3B of assets. But capex/depreciation rose 1.5× → 1.8× → 2.1× because Solventum is replicating 3M’s plants, distribution centres and ERP — forced separation capex that damages returns without improving competitive position. HIS is close to capital-free (~$3M of annual depreciation supporting a $1.36B revenue segment). The $207M finance-leased headquarters understates true capital formation by roughly that amount over the build period.

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy? This is the single weakest fact in the file. Free cash flow: $1,625M (FY2023 carve-out) → $805M (FY2024) → −$10M (FY2025, against $150–250M guided) → −$273M in Q1-2026 (versus −$80M a year earlier) → ~$200M guided for FY2026, a 1.3% yield on the current price. FCF/adjusted net income was 69% (FY2024), −1% (FY2025) and −19% TTM. Management asserts that ex-separation the “clean” figure would be approximately $1.0B and targets >80% conversion. The gap widened in the most recent quarter, and there is not yet one quarter of evidence for the convergence.

The philosophy, as demonstrated by the ~$3.89B of P&F proceeds: 79% to debt repayment, 18% to the Acera acquisition, 0% to buybacks, 0% to dividends. Deleveraging first is the correct sequencing for a company that started at ~3.8x, and net leverage is now 2.4x.

Significant acquisitions recently? One: Acera Surgical, closed 2025-12-23 for $776M total consideration (~8× upfront, ~9.4× total EV/sales on ~$90M of revenue), allocated ~90% to goodwill and intangibles. A full price, but the right shape — adjacent to an existing call point, plugged into a sales force already paid for, ~5% of enterprise value, survivable if it disappoints. The relevant counterfactual is that a newly independent company holding $4B of divestiture cash could have done something transformational and destructive. Management didn’t. That deserves credit. The unresolved concern is that Acera sells synthetic tissue matrices into the category the CY2026 CMS skin-substitute reset just repriced — and Solventum has quantified nothing while two direct competitors have disclosed material headwinds.

Buying back shares? Recently, at good prices, and at trivial scale relative to the authorisation. A $1.0B authorisation approved November 2025 saw $0 spent in FY2025 and $67M in Q1-2026 (922,636 shares at an average $72.53, with 51% of the shares bought in the cheapest month at $67.33 — a tranche now up ~20%). 93.3% remains unspent. Two caveats: the CFO describes the purpose as “offsetting the impact of our stock-based comp dilution and holding that share count relatively flat” — share-count management, not value capture; and Q1-2026 free cash flow was −$273M while total debt rose $45M in the same quarter, so the buyback is currently balance-sheet-funded, not cash-flow-funded. Do not treat the authorisation as a price floor.

Issuing large amounts of new shares to insiders? Yes, and it is the principal source of dilution. Diluted share count went 172.7M → 173.7M → 175.3M → 175.5M (~0.9%/yr). SBC rose $39M → $112M → $161M (1.9% of sales) → ~$204M annualising in Q1-2026 (2.5% of sales) — a run-rate that exceeds the current buyback pace. One-time separation awards to the five named executives totalled roughly $70.8M at target, including $44.7M for the CEO alone (hiring bonus, make-whole RSUs and cash, and $16.0M of inducement PSUs worth $45.0M at maximum). Broad one-time “founders’ RSUs” also went to employees and non-employee directors in 2024. Unvested RSUs plus PSUs at target are 2.6% of shares outstanding (3.3% if PSUs max).

Compensation policy of directors/management? The load-bearing governance weakness. There is no ROIC, ROE, ROTC or economic-profit metric anywhere in the annual incentive plan or the long-term plan. The 2025 AIP is 50% constant-currency revenue, 30% adjusted operating income, 20% adjusted free cash flow, with an individual modifier widened to ±30%. The 2025–27 PSU is 50% revenue growth, 30% adjusted EPS — a metric a $3.0B debt paydown and a $1B buyback deliver mechanically — and 20% relative TSR, added only after shareholder pushback (the 2024–26 PSU has no rTSR at all).

Worse is the FY2025 payout. Each reported “actual” contains a discretionary Talent Committee add-back: +$234M to revenue, +$64M to adjusted operating income beyond the standard non-GAAP measure, and +$540M to free cash flow. Solventum’s GAAP free cash flow for FY2025 was −$10M, and the 2026 proxy’s own performance-highlights box prints “Free Cash Flow ($10M)” on the same page that justifies a 120%-of-target FCF payout. On unadjusted results the Business Performance Factor would have been roughly 76%, not 123% — a ~47-point swing bought with discretion. And the discretion compounds: the proxy states the FCF target was set low because free cash flow “was expected to be impacted by separation costs” — and the Committee then added separation costs back to compute the actual. The same headwind was credited twice. The CEO’s individual modifier took the 123% factor to 1.48× target; his 2025 summary-table total was $20.1M, with “compensation actually paid” of $40.0M and a 245:1 pay ratio. The compensation peer group includes Danaher, Intuitive Surgical, Stryker and Medtronic — benchmarking an $8.3B, 2–3%-growth carve-out against companies several times its size.

Say-on-pay support fell from 85.9% to 74.2% two weeks after Trian’s letter.

Motivations of management? Mixed, and the evidence cuts both ways. Positive: CEO Bryan Hanson (ex-Zimmer Biomet) and CFO Wayde McMillan (ex-Insulet) are credentialed external operators who made the right structural call (selling P&F at ~4–5× the multiple their own equity commands), the right liability call (retiring 40-year 6.00% paper), the right dividend call (none), and the right M&A call (small and adjacent rather than transformational). And across 27 months and 105 Form 4s there is not a single code-S open-market sale by any Solventum officer or director — no one has sold into a stock that roughly doubled off its low. Negative: the entire group of 18 directors and executive officers owns 287,500 shares plus 125,730 acquirable — under 0.24% of the company, roughly $36M, with ownership guidelines satisfied largely by counting unvested RSUs. Total insider open-market buying since the spin is $100,344 (one director, 1,475 shares at $68.03). The CEO’s ~$10.8M of owned stock is roughly half a year’s pay.

The honest read: management is paid in equity and keeps what vests net of tax; nobody is putting personal money at risk. Read the insider record as “no negative signal,” not as conviction.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? None of these. Solventum is a Delaware corporation, incorporated 2023, headquartered in Eagan, Minnesota, filing 10-K/10-Q as a US domestic filer (CIK 0001964738), with a single class of common stock (par $0.01) listed on the New York Stock Exchange. Ordinary Form 1099 dividend/capital-gain treatment would apply; there is no K-1 and no ADR structure. The one structural quirk is the spin’s tax status: the 2024-04-01 distribution was intended to be tax-free to 3M shareholders under §355, and the Tax Matters Agreement obliges Solventum to indemnify 3M if that treatment is lost — including through a change of control under §355(e).

Dividend policy? No dividend has ever been declared or paid since inception on 2024-04-01. With ~$5.1B of debt, ~$270M of 2026 net interest, ~$400–450M of capex, guided free cash flow of ~$200M and ~$800M of the $878M year-end cash held offshore (only ~$78M domestic), a dividend would be debt-financed. Not paying one is correct. Capital return is currently entirely via a $1.0B repurchase authorisation of which 93.3% is unspent.

How profitable is the business? See the ROIC table above, and note the three-layer answer at the current price. On management-adjusted earnings — 20.5% operating margin, $6.11 FY2025 adjusted EPS, 14.2% ROIC — profitable and reasonably valued (13.2x the high end of the FY2026 guide, 10.5x EV/adjusted EBITDA). On GAAP excluding the divestiture gain — 7.6% operating margin, ~$0.20 of TTM EPS, 5.3% ROIC — barely profitable and expensive (18.5x EV/GAAP EBITDA, the joint-highest in its peer group). On tangible operating capital — ~26.6% — genuinely excellent. All three are true simultaneously, and which one an investor uses determines the entire conclusion.

Is net income diverging from cash from operations? Yes — severely, and it is the most important single fact in this file. FY2025: net income $1,556M (including $1,397M of after-tax divestiture gain) against operating cash flow of $369M and free cash flow of −$10M. Stripping the gain, GAAP net income was ~$159M; on management’s adjusted basis, $1,070M of adjusted net income converted to negative free cash flow. Q1-2026: net income $13M, operating cash flow −$189M, free cash flow −$273M, driven by accrued compensation (−$151M), amounts due to related parties (−$100M), other operating items (−$94M) and deferred taxes (−$41M).

Working capital is not the culprit — the cash conversion cycle has been flat at ~81 days and receivables are clean. The divergence is cash separation spending, cash restructuring, cash litigation defence and cash payments to 3M — precisely the items excluded from adjusted earnings. That is the mechanism, and it is why the memo treats adjusted EPS as cash-flattered rather than amortization-flattered.

Risks & Downside

What factors would cause the stock to decline? In descending order of expected impact:

1. Free cash flow fails to converge. A reverse-DCF at $86.82 requires $700M–$1,000M of levered free cash flow across the plausible WACC/growth box; FY2026 is guided to ~$200M and FY2025 delivered −$10M. Capitalised, that gap is worth roughly 68% of the enterprise value.
2. An adverse Bair Hugger bellwether verdict in 2026 establishing a settlement benchmark against a $31M accrual.
3. HIS growth breaks as Epic ships autonomous ED and radiology coding in November 2026 — 30% of segment profit, and a $32/share swing on the exit multiple alone.
4. MedSurg fails to recover from 13.1% toward the ~17.6% the FY2026 guide implicitly requires.
5. 3M distributes its 14.7% residual stake (25.57M shares, ~$2.2B) off the live S-3ASR shelf into strength.
6. A Q3-2026 disappointment when the ~$100M H1 advance-order pull-forward reverses.
7. A break-up announced at a disappointing multiple — the base sum-of-the-parts on mid-range comps is already at or slightly below the current price.
8. PFAS liability crystallises now that 3M’s indemnity has lapsed with no reserve disclosed.

Risk of a catastrophic loss? Real but low, and it has one name: Bair Hugger. More than 8,400 US suits, Solventum as the economic defendant by contract, bellwether trials anticipated in 2026, $31M accrued, no estimable range above it, and the Eighth Circuit having already revived the MDL after 3M’s 2019 summary judgment. Against $5.1B of debt, a verdict establishing a large per-claim benchmark would be a genuinely binary event. The honest mitigant is the litigation’s own decade-long record: Minnesota’s 61 state cases were resolved for 3M in 2019, and the December 2021 first federal bellwether was a defence verdict. No plaintiff verdict of scale has ever been returned. That is why the accrual is small, and it is the strongest argument that this is a tail rather than a base case.

Secondary catastrophic vectors: a supply failure at 3M for the materials behind ~$3bn (36%) of revenue, including the proprietary process behind ~$2bn (24%), where Solventum concedes it may need to “develop our own manufacturing capabilities… or identify an appropriate substitution or product reformulation”; and a §355(e) tax indemnity trigger, which is a transaction risk rather than an operating one.

Chance of a total loss? Very low. Solventum has ~$8.2B of stable, diversified, largely non-discretionary consumable revenue with no customer above 10%; net leverage of 2.4x adjusted EBITDA; a $2.0B undrawn revolver to 2029 plus a $2.0B commercial-paper programme with nothing outstanding; 77% of debt principal maturing after 2030 at a ~5.6% weighted-average fixed coupon with only 2.2% floating; and no maturity at all in 2026 or 2028. A total loss requires a mass-tort outcome an order of magnitude beyond anything in this litigation’s history, and even then the operating businesses — which earn ~27% on tangible operating capital — would retain substantial value in any restructuring. The realistic downside is the ~$46/share bear scenario, not zero.

Recent News & Events

Has the business environment changed recently? Yes, in four material ways since the FY2025 10-K.

1. CMS repriced skin substitutes effective 2026-01-01 — a $10bn Medicare Part B pool reset to a single blended $127.28/cm² rate. MiMedx wound revenue fell 60% and ConvaTec’s InnovaMatrix fell 30% with a $72M impairment. Solventum bought into this category five weeks before the rule took effect and has quantified nothing.
2. US surgical volumes turned negative and are accelerating downward — HCA same-facility inpatient surgeries −0.3% (Q1-2026) then −2.3% (Q2-2026); outpatient −1.7% then −3.4% — while hospital median operating margins fell to 2.1% in January 2026.
3. The tariff regime reset on 2026-02-20 when the Supreme Court struck down the IEEPA tariffs 6–3; a Section 122 10% global tariff replaced them within hours but is capped at 150 days, with Section 232 medical-device investigations open. Solventum reaffirmed guidance after the ruling, implying either expected re-imposition or unbooked recovery.
4. 3M’s PFAS indemnity expired 2025-12-31 and 3M ceased supplying PFAS-containing components at the same date — a liability transfer with no reserve and an attached supply problem.

Significant acquisitions? Acera Surgical, $776M, closed 2025-12-23 — the only acquisition since the spin. See above.

Change in accounting policies? No. No change in accounting principle, no restatement, no auditor change (PwC ratified 99.7% in both 2025 and 2026), and no accounting-related SEC staff comment in the entire correspondence file. The FY2025 presentation changes are transactional, not policy: P&F was not presented as discontinued operations, so FY2025 revenue of $8,325M still contains $497M of P&F, and the $1,549M gain sits in GAAP operating income. Prior-period P&F segment figures were restated for the Water Business carve-out. The 2026-07-16 appointment of Neil Zieselman as Chief Accounting Officer (effective 2026-08-10) is a four-month-noticed retirement succession with no restatement, disagreement or resignation-under-protest — not an accounting red flag.

Recent changes — new markets, facilities, management?

• Facilities: the new Eagan, Minnesota headquarters was recognised as a ~$207M finance lease in Q1-2026, with a term to 2046. Multiple new distribution centres and a final ERP cutover are scheduled through 2026, with a pre-announced ~$100M advance-ordering benefit landing in Q2-2026 that reverses in H2.
• Management: Heather Knight appointed Chief Commercial Officer (a new role overseeing all commercial functions and R&D across the three segments) effective 2025-11-10, with a $2.0M make-whole cash award and a $6.0M make-whole RSU; Chris Barry, MedSurg president, departed 2025-12-31 with severance; CAO succession announced 2026-03-24 and filled 2026-07-16. A new Executive Severance Plan effective 2026-06-01 cut CEO-direct-report severance from 18 to 12 months of base salary and added forfeiture provisions.
• Markets: no new geographies. The strategic motion is the reverse — portfolio contraction: P&F divested, a ~100bp SKU-rationalisation drag in 2026, orthodontics declining and undefended, and an explicit CEO statement that “the further the spin gets in the rearview mirror, the more flexibility we have” on further separations.
• Ownership: Trian went public on 2026-04-30 with ~4.1%; 3M sold 8.8M shares at $73.45 in August 2025 and retains 25.57M (14.7%) with sole dispositive power and a live shelf.

This appendix carries no recommendation and no price target. General information only — not investment advice.

APPENDIX B — Source Appendix

Solventum Corporation (NYSE: SOLV) — 2026-07-31

All sources accessed 2026-07-31 unless otherwise stated. Primary sources (SEC filings, company disclosure) take precedence over third-party aggregated data throughout; where an aggregator and a filing disagree, the filing governs and the discrepancy is noted in the text.

B.1 Primary — SEC filings (Solventum Corporation, CIK 0001964738)

The complete trailing 60-month corpus was enumerated and reviewed via SEC EDGAR. Form-type counts: 2 × 10-K, 7 × 10-Q, 30 × 8-K, 2 × DEF 14A, 2 × DEFA14A, 105 × Form 4, 4 × Form 3, 1 × Form 4-A, 1 × 10-12B, 2 × 10-12B-A, 1 × S-4, 1 × S-3ASR, 1 × S-8, 1 × POS AM, 1 × ARS, 2 × SD, 7 × DRS-A, 6 × DRSLTR, 1 × DRS, 2 × SEC staff letters, 1 × SEC staff action.

Annual reports

Quarterly reports

Current reports (Form 8-K) — the material-event timeline

Earnings-release exhibits (EX-99.1) to the 2.02 filings above are the source for all non-GAAP reconciliations, the GAAP→adjusted operating-income bridge, adjusted EPS by quarter, and the guidance-versus-delivery history.

Proxy statements

Ownership and insider filings

• 105 × Form 4, 4 × Form 3, 1 × Form 4-A (2024-03-26 through 2026-07). Re-parsed in full for this report; the transaction-code analysis in the insider-activity discussion (zero code-S officer/director sales; one code-P purchase — Amy McBride Wendell, 1,475 shares at $68.03, 2026-03-10, filed 2026-03-11; 3M’s 8,800,000-share code-S sale at $73.45 on 2025-08-15; code J entries for the 3M contribution and distribution) derives from the raw filings, not from a helper parser.

Registration statements and staff correspondence

• S-4, filed 2024-11-15 (with POS AM, 2024-12-11) — registered A/B exchange of the $6.9B of 144A senior notes for identical registered notes; source for tranche coupons and maturities.
• S-3ASR, filed 2025-08-13 — automatic shelf enabling 3M’s resale two days later; the live overhang referenced in the insider and ownership discussion.
• S-8, filed 2024-04-01 — 2024 LTIP, ESPP and VIP Excess Plan.
• SEC staff letters, 2024-02-27 and 2024-03-13, and the associated staff action — Corp Fin comments on redactions in Form 10 Exhibits 10.4, 10.9 and 10.10 (the 3M supply and transition agreements), closed with “We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements.” Cited as evidence of a clean accounting comment file.

B.2 Primary — earnings-call transcripts

Transcripts were sourced publicly (The Motley Fool). All management statements are treated as hypotheses requiring external validation, as a matter of standing practice.

B.3 Market, price and factor data

B.4 Third-party industry, competitor and regulatory sources

Activist and ownership

• Trian Fund Management — open letter and presentation to the Solventum board, “Solventum’s Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value,” GlobeNewswire, 2026-04-30; Reuters coverage, 2026-05-01. Stake reported at ~7.09M shares (~4.1%).

Competitor filings and reports (used for the return-on-capital cross-section, the comparables table and the sum-of-the-parts anchors)

• Becton Dickinson FY2025; Baxter International; Zimmer Biomet FY2025; Medtronic FY2026; STERIS FY2026 (including Applied Sterilization Technologies segment margin); GE HealthCare; Alcon; Smith+Nephew FY2025 (Advanced Wound Care / Bioactives / Devices split; 24.9% wound trading margin); ConvaTec FY2025 (56.2% gross margin; InnovaMatrix −30% and $72M impairment; quantified 2% FY26 headwind); Coloplast; Mölnlycke; Align Technology FY2025; Envista FY2025; Dentsply Sirona FY2025 (net loss $598M; $650M impairments; dividend cancelled); Straumann Annual Report 2025 (+8.9% organic; 26.5% core EBIT margin; Q4-25 APAC organic −12.8%); Mesa Laboratories FY2026 (Sterilization & Disinfection Control segment 71.3% gross margin, +8.7% organic, +17.7% in Q4); MiMedx; Waystar; Health Catalyst; Evolent Health.
• HCA Healthcare Q1-2026 and Q2-2026 results — same-facility admissions and inpatient/outpatient surgical volumes.

Healthcare IT market structure

• KLAS Research, US acute-care EHR market share, 2026-05-14 — Epic 43.7% of hospitals and 56.9% of beds; Oracle Health −56 hospitals.
• 2026 Best in KLAS awards — Computer-Assisted Coding (Dolbey, tenth consecutive year), CDI (Microsoft Nuance), inaugural Autonomous Coding (CodaMetrix), ambient documentation (Abridge). Solventum won none of the six adjacent categories.
• Epic public product communications — Penny revenue-cycle agent (240+ organisations), NoteReader CDI, and the November 2026 launch of fully autonomous ED and radiology coding.
• Solventum public product pages — inpatient and ED autonomous coding listed as “Coming soon”; installed base of 195 facilities / 5.4M encounters.
• Rock Health digital-health funding data — $14.2bn of 2025 healthcare-AI venture funding (+35% on 5% fewer deals); M&A count 118 (2024) → 195+ (2025) → 115 in H1-2026; retirement of the “AI deal” classification in Q1-2026.

Reimbursement and regulation

• CMS, CY2026 Medicare Physician Fee Schedule final rule — skin substitutes reclassified from biologicals to “incident-to” supplies at a single blended $127.28/cm² rate effective 2026-01-01.
• HHS Office of Inspector General — Medicare Part B skin-substitute spending, $252M (2019) to over $10bn (2024).
• CMS ICD-10-CM code-set updates — new codes 252 (FY2025) → 487 (FY2026) → 190 (FY2027); FY2027 IPPS proposed rule (severity-tiered MS-DRG consolidation).
• CMS HCC v28 — HCC categories 86 → 115 while mappable ICD-10-CM codes fell 9,797 → 7,770 (−21%).
• State Medicaid regulations citing Solventum’s APR-DRG grouper by name and version: Mississippi (v43), South Carolina (v32→v42), Wisconsin (v42), Florida (v43), Missouri (adopted July 2025).
• ANSI/AAMI ST79 — biological-indicator requirements for sterilization loads containing implants; Joint Commission audit standards.
• FDA determination on fluoropolymers in medical devices, 2025-08-06.
• ECHA / European Commission — March-2026 EU PFAS restriction with increased fluoropolymer derogations; EU MDR simplification proposal, 2025-12-16 (estimated >€3.3bn of annual savings; removal of fixed five-year recertification).
• US Supreme Court decision striking down the IEEPA tariffs 6–3, 2026-02-20; subsequent Section 122 10% global tariff (150-day cap) and open Section 232 medical-device investigations.
• China Volume-Based Procurement 2.0 — framework due July 2026, supplier selection August 2026, orthodontic brackets in scope; 2023 dental-implant VBP precedent (~63% price reduction).

Dental end-market data

• ADA Health Policy Institute — real US consumer spending on dental $185bn (Jan-2020) → $201bn (Sep-2025), +9%, against physician services +24% and overall health care +22%; dentists reporting “not busy enough” 24% (Q4-2024) → 33% (Q4-2025); new-patient wait times 22.7 → 13.4 days; indexed cost series (Jan-2015 = 100): dental staff wages 144, CPI 138, dental supplies PPI 129 (Sep-2025).
• DSO affiliation data — 16.1% of dentists affiliated; 27% among those fewer than ten years from graduation; ~130 PE-backed platforms.

Hospital operating environment

• Kaufman Hall / national hospital flash reports — median hospital operating margin 4.9% (December 2025) → 2.1% (January 2026); expenses and labour +5% year-on-year; 40% of executives planning to cut or defer capital spending.

Litigation record

• In re Bair Hugger Forced Air Warming Devices Products Liability Litigation, MDL No. 2666 (D. Minn.) — 2019 summary judgment for 3M, reversed by the Eighth Circuit (2021); December 2021 first federal bellwether returned a defence verdict; Minnesota’s 61 state cases resolved for 3M in 2019; bellwether and state trials anticipated in 2026.
• United States ex rel. Hartpence v. Kinetic Concepts — settled 2025-05-15; dismissed with prejudice as to the relator 2025-07-03.
• Gilbert v. Solventum (Del. Ch., filed 2024-05-10) — bylaw challenge; closed 2026-06-02, $120,000 of plaintiff fees paid.

B.5 Analytical frameworks

• Bruce C. Greenwald & Judd Kahn, Competition Demystified — barriers to entry as the dominant question; the three genuine advantage types (supply/cost, demand/captivity, economies of scale plus captivity); the market-share-stability test and its calibration; the sustained-ROIC test (15–25% indicates advantage, 6–8% indicates its absence).
• Edward Chancellor (ed.), Capital Returns (Marathon Asset Management) — supply-side capital-cycle analysis; the asset-growth anomaly; the carve-out that the cycle does not operate normally where technology disrupts the business model, applied to healthcare coding in the Industry Dynamics section.